U.S. patent application number 12/957480 was filed with the patent office on 2012-03-22 for polypeptide carrier protein.
Invention is credited to Guido Grandi, Rino Rappuoli.
Application Number | 20120070456 12/957480 |
Document ID | / |
Family ID | 10831030 |
Filed Date | 2012-03-22 |
United States Patent
Application |
20120070456 |
Kind Code |
A1 |
Rappuoli; Rino ; et
al. |
March 22, 2012 |
POLYPEPTIDE CARRIER PROTEIN
Abstract
The invention relates to polypeptide carrier proteins that
comprise at least five CD4+ T cell epitopes, for conjugation to
capsular polysaccharides. The carrier proteins are useful as
components of vaccines that can elicit a T-cell dependent immune
response. These vaccines are particularly useful to confer
protection against infection from encapsulated bacteria in infants
between the ages of 3 months and about 2 years.
Inventors: |
Rappuoli; Rino; (Castelnuovo
Berardena, IT) ; Grandi; Guido; (Segrate,
IT) |
Family ID: |
10831030 |
Appl. No.: |
12/957480 |
Filed: |
December 1, 2010 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12383545 |
Mar 25, 2009 |
7867498 |
|
|
12957480 |
|
|
|
|
11030635 |
Jan 6, 2005 |
7538207 |
|
|
12383545 |
|
|
|
|
09674183 |
Nov 14, 2000 |
6855321 |
|
|
PCT/IB99/00844 |
Apr 27, 1999 |
|
|
|
11030635 |
|
|
|
|
Current U.S.
Class: |
424/189.1 ;
424/186.1; 424/190.1; 424/191.1; 435/252.33; 435/254.2; 435/254.21;
435/254.22; 435/254.23; 435/320.1; 435/69.3; 530/350; 530/395;
536/23.4; 800/13 |
Current CPC
Class: |
C07K 14/33 20130101;
Y02A 50/30 20180101; A61P 31/04 20180101; C07K 14/005 20130101;
Y10S 530/806 20130101; A61P 31/14 20180101; Y10S 530/822 20130101;
A61P 33/02 20180101; Y10S 424/832 20130101; Y10S 530/807 20130101;
C07K 14/34 20130101; Y02A 50/412 20180101; C07K 14/235 20130101;
Y10S 424/831 20130101; A61K 38/00 20130101; A61K 39/00 20130101;
A61P 37/04 20180101; C12N 2730/10122 20130101; C07K 14/22 20130101;
C07K 2319/00 20130101; C12N 2760/16222 20130101; Y10S 530/825
20130101; A61P 31/16 20180101; C07K 14/445 20130101; Y10S 530/826
20130101; A01K 2217/05 20130101 |
Class at
Publication: |
424/189.1 ;
530/350; 530/395; 424/190.1; 424/191.1; 424/186.1; 536/23.4;
435/320.1; 435/252.33; 800/13; 435/69.3; 435/254.2; 435/254.22;
435/254.21; 435/254.23 |
International
Class: |
A61K 39/29 20060101
A61K039/29; C07K 17/10 20060101 C07K017/10; A61K 39/385 20060101
A61K039/385; A61K 39/08 20060101 A61K039/08; A61K 39/015 20060101
A61K039/015; A61K 39/145 20060101 A61K039/145; A61K 39/05 20060101
A61K039/05; A61K 39/095 20060101 A61K039/095; A61K 39/10 20060101
A61K039/10; C07H 21/04 20060101 C07H021/04; A61P 31/04 20060101
A61P031/04; A61P 31/14 20060101 A61P031/14; A61P 31/16 20060101
A61P031/16; A61P 33/02 20060101 A61P033/02; C12N 1/21 20060101
C12N001/21; A01K 67/027 20060101 A01K067/027; C12P 21/00 20060101
C12P021/00; C12N 1/19 20060101 C12N001/19; C07K 17/02 20060101
C07K017/02 |
Foreign Application Data
Date |
Code |
Application Number |
Apr 27, 1998 |
GB |
0908932.9 |
Claims
1. A carrier protein comprising at least five CD4+ T cell
epitopes.
2. A carrier protein according to claim 1, wherein the CD4+
epitopes are derived from a pathogenic bacterium or virus.
3. A carrier protein according to claim 1, wherein the CD4+
epitopes are derived from tetanus toxin, Plasmodium falciparum
circurnsporozite protein, hepatitis B surface antigen, hepatitis B
nuclear core protein, influenza matrix protein, influenza
haernagglutinin, diptheria toxoid, diptheria toxin mutant CRM 197,
group B Neisseria meningitidis outer membrane protein complex,
pertussis toxin or heat shock protein 70.
4. A carrier protein according to claim 1, wherein the CD4+
epitopes are selected from P23TT, P32TT, P21TT, PfCs, MOTT, P2TT,
HBVnc, HA, HbsAg, MT and hsp70 CD4+ epitopes.
5. A carrier protein according to claim 1, that comprises the
P23TT, P32TT, P21TT, PfCs, MOTT, P2TT, HBVnc, HA, HbsAg and MT CD4+
epitopes.
6. A carrier protein according to claim 1, that comprises the
P23TT, P32TT, P21TT, PfCs, P3 OTT, P2TT, HBVnc, HA, HbsAg, MT and
hsp70 CD4+ epitopes.
7. A carrier protein according to claim 1, that comprises the
P23TT, P32TT, P21TT, PfCs, P30TT and P2TT CD4+ epitopes.
8. A carrier protein according claim 1, wherein the CD4+ epitopes
are human CD4+ epitopes.
9. A carrier protein which comprises one or more of N6, N10 or N19
proteins.
10. A carrier protein according to claim 1, in an oligomeric
form.
11. A carrier protein according to claim 1, conjugated to a
polysaccharide.
12. A carrier protein according to claim 11, wherein the
polysaccharide is an Haemophilus influenzae type B
polysaccharide.
13. A carrier protein according to claim 11, wherein the
polysaccharide is derived from S. pneumoniae, N. meningitidis, S.
aureus, Klebsiella, or S. typhimurium.
14. A carrier protein according to claim 11, wherein the
polysaccharide is conjugated to the protein by a covalent
linkage.
15. A carrier protein according to claim 11, wherein the
polysaccharide is conjugated to the protein by reductive
amination.
16. A carrier protein according to claim 11, wherein there are
between two and ten protein units for each polysaccharide unit.
17. A composition comprising the carrier protein of claim 1.
18. A method of vaccinating a mammalian subject comprising
administering the carrier protein of claim 1 to said subject.
19. A method of protecting a mammalian subject from a disease
caused by an encapsulated bacterium comprising administering the
carrier protein of claim 1 to said subject.
20. A nucleic acid molecule which encodes a carrier protein
according to claim 1.
21. The nucleic acid molecule of claim 20 which comprises DNA.
22. A cloning or expression vector comprising a nucleic acid
molecule according to claim 20.
23. A host cell transformed or transfected with the vector of claim
22.
24. A transgenic animal that has been transformed by a nucleic acid
molecule according to claim 20.
25. A transgenic animal that has been transformed by the vector of
claim 22.
26. A method of preparing a carrier protein comprising expressing a
vector according to claim 22 in a host cell and culturing said host
cell under conditions where said protein is expressed, and
recovering said expressed protein.
27. The method of claim 26, further comprising the step of
conjugating the recovered protein to a polysaccharide.
28. The method of claim 26, wherein the host cell is an E. coli
bacterium.
29. A method of producing a carrier protein according to claim 1,
comprising (a) constructing oligonucleotide molecules that encode
said epitopes; (b) annealing the oligonucleotide molecules to form
duplexes; (c) introducing the oligonucleotide duplexes into an
expression vector so as to encode a fusion protein; (d) introducing
the expression vector into a host cell to allow expression of the
fusion protein; and (e) isolating the fusion protein produced from
a culture of said host cells.
30. The method of claim 29, further comprising (f) conjugating the
fusion protein to a polysaccharide.
31. The method of claim 29, wherein the host cell is an E. coli
bacterium.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser.
No. 12/383,545, filed Mar. 25, 2009, which is a divisional of U.S.
application Ser. No. 11/030,635, filed Jan. 6, 2005, which is a
continuation of U.S. application Ser. No. 09/674,183, filed Nov.
14, 2000, now U.S. Pat. No. 6,855,321, which claims priority to PCT
Application No. PCT/IB99/00844, filed Apr. 27, 1999, which claims
priority to GB Application No. 908932.9, filed Apr. 27, 1998, from
which applications priority is claimed pursuant to 35 U.S.C.
.sctn.120 and 35 U.S.C. .sctn.119, all of which applications are
incorporated herein by reference in their entireties.
TECHNICAL FIELD
[0002] The present invention relates to polyepitope carrier
proteins. When conjugated to capsular polysaccharides, these
carrier proteins are useful as components of vaccines that are
capable of eliciting a T-cell dependent immune response.
Particularly, the proteins of the present invention may be used to
confer protection against infection from encapsulated bacteria in
infants between the ages of 3 months and about 2 years.
BACKGROUND
[0003] Encapsulated bacteria such as Haemophilus influenzae,
Neisseria meningitidis and Streptococcus pneumoniae constitute a
significant cause of morbidity and mortality in neonates and
infants world-wide (Tunkel & Scheld, 1993). In developing
countries, around one million children die each year due to
pneumonia alone. Furthermore, even in developed countries, the
increase in the phenomenon of antibiotic resistance means that
there is a great need to improve on existing vaccines.
[0004] The polysaccharide capsule of H. influenzae, N. meningitidis
and S. pneumoniae represents a major virulence factor that is
important for nasopharyngeal colonisation and systemic invasion by
encapsulated bacteria (Moxon and Kroll, 1990). Consequently, much
of the research directed toward finding protective immunogens has
focused on capsular polysaccharides. The finding that these
polysaccharides are able to elicit the formation of protective
antibodies led to the development of a number of vaccines that have
been efficacious in protecting adults from disease (Andreoni et al.
1993; Goldblatt et al. 1992).
[0005] The problem with capsular polysaccharide vaccines developed
to date is that they suffer an inherent inability to protect
children under two years of age from disease (Holmes and Granoff
1992). This is a significant drawback when it is appreciated that
this population of children is at highest risk of infection. Their
failure to block infection is believed to derive from the T-cell
independent (TI) type of immune reaction that is the only antibody
response used by the body against polysaccharide antigens. This
type of response does not involve MHC Class II restriction
molecules for antigen presentation to T-cells; as a consequence,
T-cell help is prevented. Although the TI response works well in
adults, it is inactive in very young children due to a combination
of factors such as functional B-cell immaturity, inactivation of
B-cell receptor-mediated signalling and B-cell anergy in response
to antigen stimulation.
[0006] To overcome this drawback, two particular vaccine approaches
are currently being investigated. The first is the development of
anti-idiotype vaccines that contain peptides that mimic
carbohydrate idiotypes (McNamara 1984; Agadjanyan, 1997). The
second approach involves conjugate vaccines that are designed to
transform T-cell independent (TI) polysaccharide antigens into
T-dependent (TD) antigens through the covalent linkage of the
polysaccharide to a peptide carrier.
[0007] H. influenzae type B (Hib) conjugate vaccines represent a
leading example for the development of other vaccines against
infections that are due to capsulated bacteria. In fact, meningitis
and other infections caused by Hib have declined dramatically in
countries where widespread vaccination with Hib conjugate has been
achieved (Robins, 1996). Complete elimination of the pathogen might
be possible, but depends upon several factors, including a further
improvement of the existing vaccines (Liptak, 1997).
[0008] The widely distributed paediatric vaccine antigens tetanus
and diptheria toxoids have been selected as carrier proteins with
the aim of taking advantage of an already-primed population at the
time of conjugate vaccine injection. Previous vaccination with
paediatric diptheria-tetanus (DT) or diptheria-tetanus-pertussis
(DTP) vaccines means that carrier priming may now be exploited to
enhance the immune response to polysaccharide conjugates.
[0009] A number of such vaccines have been successfully produced
and have been efficacious in reducing the number of deaths caused
by these pathogens. The carriers used in these vaccines are large
antigens such as tetanus toxoid, non-toxic diptheria toxin mutant
CRM197 and group B N. meningitidis outer membrane protein complex
(OMPC). However, in the future, it is thought that as the number of
conjugate vaccines containing the same carrier proteins increases,
the suppression of immune responses by pre-existing antibodies to
the carrier is likely to become a problem.
[0010] Much research is now being directed to the development of
improved carrier molecules that contain carrier peptides comprising
CD4+ T helper cell (Th) epitopes, but which do not possess T-cell
suppressive (Ts) functions (Etlinger et al. 1990). Peptides which
retain only helper functions (CD4+ epitopes) are most suitable as
carriers, since their effect is sufficient to induce T cell help
but the carrier is small enough to limit or to completely avoid
production of anti-carrier antibodies.
[0011] Various publications demonstrate the ability of such
peptides to confer T-cell help to haptens when covalently linked to
them (Etlinger, 1990; Valmori 1992; Sadd 1992; Kumar 1992;
Kaliyaperumal, 1995; De Velasco, 1995 and Bixler 1989). However, to
date, these publications have not resulted in the development of
effective vaccines. There thus remains a great need for the
development of new, improved vaccine strategies that are effective
in combating diseases caused by encapsulated bacteria in infants
and young children.
SUMMARY OF THE INVENTION
[0012] According to the present invention, there is provided a
carrier protein comprising at least five CD4+ T-cell epitopes.
Preferably, the carrier protein is conjugated to a polysaccharide.
These compounds are useful as immunogenic compounds that may in
turn be useful as components of protective vaccines against
diseases caused by bacterial pathogens.
[0013] A carrier protein is an antigenic polypeptide entity that
induces the formation of antibodies directed against an antigen
conjugated to it, by the immune system of an organism into which
the carrier-antigen conjugate is introduced. The necessity to use
carrier proteins results from the fact that although many short
epitopes are protective, they are poorly immunogenic. This negates
the usefulness of these epitopes in the generation of new and
efficacious vaccines. By conjugating an immunogenic carrier protein
to a molecule that is non-immunogenic, it is possible to confer the
high immunogenicity of the carrier protein onto the conjugate
molecule. Such conjugate molecules stimulate the generation of an
immune response against the non-immunogenic portion of the
conjugate molecule and thus have been effectively used in vaccines
that protect against pathogens for which protective immunity could
not otherwise be generated.
[0014] Hence, highly immunogenic proteins (such as tetanus toxoid)
have historically been used as carriers in order to induce a Th
cell response that provides help to B cells for the production of
antibodies directed against non-immunogenic epitopes. However,
overall effectiveness has not been generally achieved with this
approach, since the antibody response to a hapten (the epitope)
coupled to a carrier protein can be inhibited when the recipient
host has been previously immunised with the unmodified carrier
protein. This phenomenon is termed epitope-specific suppression and
has now been studied in a variety of hapten-carrier systems.
[0015] Coupling of bacterial polysaccharides to carrier proteins
has been shown to improve the immunogenicity of the polysaccharide
and results in antigens with novel characteristics. Furthermore,
the coupling of a thymus-independent (TI) polysaccharide to a
protein makes the polysaccharide thymus-dependent (TD).
[0016] A CD4+ T cell epitope is a peptide epitope that stimulates
the activity of those T cells that are MHC Class II restricted.
This subset of T cells includes Th cells. Many CD4+ epitopes are
well known to those of skill in the art and have been shown to
confer T cell help to haptens when covalently attached to them
(Etlinger et al, 1990; Valmori 1992; Sadd 1992; Kumar 1992;
Kaliyaperumal, 1995).
[0017] The CD4+ T epitopes used in the carrier proteins of the
present invention ideally comprise peptides that are of as short a
length as possible. The epitope will thus retain its
characteristics to a sufficient degree to induce T-cell help, yet
will be small enough that excessive production of anti-carrier
antibodies will be minimised. This is preferable, since it is
thought that suppression of immune responses by pre-existing
antibodies to carrier epitopes is likely to become a problem in the
future if the number of congregate vaccines containing common
carrier proteins keeps growing. Furthermore, the use of short
peptides as carrier epitopes affords the rational selection of
suitable Th epitopes, whilst avoiding stretches of sequence that
contain B-cell or T-suppressor epitopes that will be detrimental to
the function of the protein in eliciting a TI immune response.
[0018] Suitable proteins from which CD4+ epitopes may be selected
include tetanus toxin (TT), Plasmodium falciparum circumsporozite,
hepatitis B surface antigen, hepatitis B nuclear core protein, H.
influenzae matrix protein, H. influenzae haemagglutinin, diphtheria
toxoid, diphtheria toxoid mutant CRM197, group B N. meningitidis
outer membrane protein complex (OMPC), the pneumococcal toxin
pneumolysin, and heat shock proteins from Mycobacterium bovis and
M. leprae. The M. leprae HSP70 408-427 epitope is not found in the
corresponding human homologous sequence (Adams et al., 1997 Infect
Immun, 65: 1061-70); since a possible limitation in the use of HSP
motifs in vaccine formulations is the possibility to induce
autoimmune responses due to the high homology between microbial and
human HSPs, this epitope is particularly preferred. Other suitable
carrier peptide epitopes will be well known to those of skill in
the art. The CD4+ T-cell epitopes selected from these antigens are
recognised by human CD4+ T cells.
[0019] It has been found that the number of T-cell epitopes present
in the carrier protein has a significant influence in conferring
T-cell help to oligosaccharide molecules conjugated thereto. The
polyepitope carrier protein should contain five or more CD4+ T-cell
epitopes. Preferably, the polyepitope carrier protein contains
between 5 and 50 degenerate CD4+ T-cell epitopes, more preferably
between 5 and 20 epitopes, even more preferably 5, 6, 7, 8, 9, 10,
11 or 19 degenerate CD4+ T-cell epitopes. The use of a number of
universal epitopes in the carrier protein has been found to reduce
the problem of genetic restriction of the immune response generated
against peptide antigens.
[0020] In addition to CD4+ epitopes, the carrier proteins of the
present invention may comprise other peptides or protein fragments,
such as epitopes from immunomodulating cytokines such as
interleukin-2 (IL-2) or granulocyte-macrophage colony stimulating
factor (GM-CSF). Promiscuous peptides (Panina-Bordignon et al
1989), the so-called "universal" peptides (Kumar et al., 1992),
cluster peptides (Ahlers et al., 1993) or peptides containing both
T cell and B cell epitopes (Lett et al, 1994) may also be used to
recruit various effector systems of the immune system, as
required.
[0021] The polyepitope carrier protein may be produced by any
suitable means, as will be apparent to those of skill in the art.
Two preferred methods of construction of carrier proteins according
to the invention are direct synthesis and by production of
recombinant protein. Preferably, the polyepitope carrier proteins
of the present invention are produced by recombinant means, by
expression from an encoding nucleic acid molecule. Recombinant
expression has the advantage that the production of the carrier
protein is inexpensive, safe, facile and does not involve the use
of toxic compounds that may require subsequent removal.
[0022] When expressed in recombinant form, the carrier proteins of
the present invention are generated by expression from an encoding
nucleic acid in a host cell. Any host cell may be used, depending
upon the individual requirements of a particular vaccine system.
Preferably, bacterial hosts are used for the production of
recombinant protein, due to the ease with which bacteria may be
manipulated and grown. The bacterial host of choice is Escherichia
coli.
[0023] Preferably, if produced recombinantly, the carrier proteins
are expressed from plasmids that contain a synthetic nucleic acid
insert. Such inserts may be designed by annealing oligonucleotide
duplexes that code for the CD4+ T-cell epitopes. The 5' and 3' ends
of the synthetic linkers may be designed so as to anneal to each
other. This technique allows annealing of the oligonucleotides in a
random order, resulting in a mixture of potentially different
mini-genes comprising any one of a number of possible combinations
of epitopes. This mixture is then cloned into any suitable
expression vector and a selection process of expressing clones is
then performed. This strategy ensures that only those clones are
selected that produce a carrier protein that is not detrimental to
the health of the cell in which it is expressed. Conversely,
arbitrary selection of the order of epitopes has been found to be
less successful.
[0024] The ends of the epitope-encoding linkers may be designed so
that two codons are introduced between the individual epitopes when
annealing takes place. Amino acid residues such as glycine or
lysine are examples of suitable residues for use in the spacers. In
particular, the use of lysine residues in spacers allows the
further congregation of carrier protein to capsular polysaccharide.
Additionally, the insertion site in the expression plasmid into
which the nucleic acid encoding carrier protein is cloned may allow
linkage of the polyepitope carrier protein to a tag, such as the
"flag" peptide or polyhistidine. This arrangement facilitates the
subsequent purification of recombinant protein.
[0025] Nucleic acid encoding the polyepitope carrier protein may be
cloned under the control of an inducible promoter, so allowing
precise regulation of carrier protein expression. Suitable
inducible systems will be well known to those of skill in the art
and include the well-known lac system (Sambrook et al. 1989).
[0026] Methods of recombinant expression of carrier proteins
according to the invention will be well known to the skilled
artisan, but for the purposes of clarity are briefly discussed
herein.
[0027] Mammalian expression systems are known in the art. A
mammalian promoter is any DNA sequence capable of binding mammalian
RNA polymerase and initiating the downstream (3') transcription of
a coding sequence (e.g. structural gene) into mRNA. A promoter will
have a transcription initiating region, which is usually placed
proximal to the 5' end of the coding sequence, and a TATA box,
usually located 25-30 base pairs (bp) upstream of the transcription
initiation site. The TATA box is thought to direct RNA polymerase
II to begin RNA synthesis at the correct site. A mammalian promoter
will also contain an upstream promoter element, usually located
within 100 to 200 bp upstream of the TATA box. An upstream promoter
element determines the rate at which transcription is initiated and
can act in either orientation [Sambrook et al. (1989) "Expression
of Cloned Genes in Mammalian Cells." In Molecular Cloning: A.
Laboratory Manual, 2nd ed.].
[0028] Mammalian viral genes are often highly expressed and have a
broad host range; therefore sequences encoding mammalian viral
genes provide particularly useful promoter sequences. Examples
include the SV40 early promoter, mouse mammary tumour virus LTR
promoter, adenovirus major late promoter (Ad MLP), and herpes
simplex virus promoter. In addition, sequences derived from
non-viral genes, such as the murine metallothionein gene, also
provide useful promoter sequences. Expression may be either
constitutive or regulated (inducible), depending on the promoter
can be induced with glucocorticoid in hormone-responsive cells.
[0029] The presence of an enhancer element (enhancer), combined
with the promoter elements described above, will usually increase
expression levels. An enhancer is a regulatory DNA sequence that
can stimulate transcription up to 1000-fold when linked to
homologous or heterologous promoters, with synthesis beginning at
the normal RNA start site. Enhancers are also active when they are
placed upstream or downstream from the transcription initiation
site, in either normal or flipped orientation, or at a distance of
more than 1000 nucleotides from the promoter [Maniatis et al.
(1987) Science 236:1237; Alberts et al. (1989) Molecular Biology of
the Cell, 2nd ed.]. Enhancer elements derived from viruses may be
particularly useful, because they usually have a broader host
range. Examples include the SV40 early gene enhancer [Dijkema et al
(1985) EMBO J. 4:761] and the enhancer/promoters derived from the
long terminal repeat (LTR) of the Rous Sarcoma Virus [Gorman et al.
(1982b) Proc. Natl. Acad. Sci. 79:6777] and from human
cytomegalovirus [Boshart et al. (1985) Cell 41:521]. Additionally,
some enhancers are regulatable and become active only in the
presence of an inducer, such as a hormone or metal ion
[Sassone-Corsi and Borelli (1986) Trends Genet. 2:215; Maniatis et
al. (1987) Science 236:1237].
[0030] A DNA molecule may be expressed intracellularly in mammalian
cells. A promoter sequence may be directly linked with the DNA
molecule, in which case the first amino acid at the N-terminus of
the recombinant protein will always be a methionine, which is
encoded by the ATG start codon. If desired, the N-terminus may be
cleaved from the protein by in vitro incubation with cyanogen
bromide.
[0031] Alternatively, foreign proteins can also be secreted from
the cell into the growth media by creating chimeric DNA molecules
that encode a fusion protein comprised of a leader sequence
fragment that provides for secretion of the foreign protein in
mammalian cells. Preferably, there are processing sites encoded
between the leader fragment and the foreign gene that can be
cleaved either in vivo or in vitro. The leader sequence fragment
usually encodes a signal peptide comprised of hydrophobic amino
acids which direct the secretion of the protein from the cell. The
adenovirus tripartite leader is an example of a leader sequence
that provides for secretion of a foreign protein in mammalian
cells.
[0032] Usually, transcription termination and polyadenylation
sequences recognised by mammalian cells are regulatory regions
located 3' to the translation stop codon and thus, together with
the promoter elements, flank the coding sequence. The 3' terminus
of the mature mRNA is formed by site-specific post-transcriptional
cleavage and polyadenylation [Birnstiel et al. (1985) Cell 41:349;
Proudfoot and Whitelaw (1988) "Termination and 3' end processing of
eukaryotic RNA. In Transcription and splicing (ed. B. D. Hames and
D. M. Glover); Proudfoot (1989) Trends Biochem. Sci. 14:105]. These
sequences direct the transcription of an mRNA which can be
translated into the polypeptide encoded by the DNA. Examples of
transcription terminator/polyadenylation signals include those
derived from SV40 [Sambrook et al (1989) "Expression of cloned
genes in cultured mammalian cells." In Molecular Cloning: A
Laboratory Manual].
[0033] Some genes may be expressed more efficiently when introns
(also called intervening sequences) are present. Several cDNAs,
however, have been efficiently expressed from vectors that lack
splicing signals (also called splice donor and acceptor sites) [see
e.g., Gothing and Sambrook (1981) Nature 293:620]. Introns are
intervening noncoding sequences within a coding sequence that
contain splice donor and acceptor sites. They are removed by a
process called "splicing," following polyadenylation of the primary
transcript [Nevins (1983) Annu. Rev. Biochem. 52:441; Green (1986)
Annu. Rev. Genet. 20:671; Padgett et al. (1986) Annu. Rev. Biochem.
55:1119; Krainer and Maniatis (1988) "RNA splicing." In
Transcription and splicing (ed. B. D. Hames and D. M. Glover)].
[0034] Usually, the above-described components, comprising a
promoter, polyadenylation signal, and transcription termination
sequence are put together into expression constructs. Enhancers,
introns with functional splice donor and acceptor sites, and leader
sequences may also be included in an expression construct, if
desired. Expression constructs are often maintained in a replicon,
such as an extrachromosomal element (e.g., plasmids) capable of
stable maintenance in a host, such as mammalian cells or bacteria.
Mammalian replication systems include those derived from animal
viruses, which require trans-acting factors to replicate. For
example, plasmids containing the replication systems of
papovaviruses, such as SV40 [Gluzman (1981) Cell 23:175] or
polyomavirus, replicate to extremely high copy number in the
presence of the appropriate viral T antigen. Additional examples of
mammalian replicons include those derived from bovine
papillomavirus and Epstein-Barr virus. Additionally, the replicon
may have two replicator systems, thus allowing it to be maintained,
for example, in mammalian cells for expression and in a prokaryotic
host for cloning and amplification. Examples of such
mammalian-bacteria shuttle vectors include pMT2 [Kaufman et al.
(1989) Mol. Cell. Biol. 9:946 and pHEBO [Shimizu et al. (1986) Mol.
Cell. Biol. 6:1074].
[0035] The transformation procedure used depends upon the host to
be transformed. Methods for introduction of heterologous
polynucleotides into mammalian cells are known in the art and
include dextran-mediated transfection, calcium phosphate
precipitation, polybrene mediated transfection, protoplast fusion,
electroporation, encapsulation of the polynucleotide(s) in
liposomes, and direct microinjection of the DNA into nuclei.
[0036] Mammalian cell lines available as hosts for expression are
known in the art and include many immortalised cell, lines
available from the American Type Culture Collection (ATCC),
including but not limited to, Chinese hamster ovary (CHO) cells,
HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells
(COS), human hepatocellular carcinoma cells (e.g., Hep G2), and a
number of other cell lines.
[0037] The polynucleotide encoding the protein can also be inserted
into a suitable insect expression vector, and is operably linked to
the control elements within that vector. Vector construction
employs techniques that are known in the art. Generally, the
components of the expression system include a transfer vector,
usually a bacterial plasmid, which contains both a fragment of the
baculovirus genome, and a convenient restriction site for insertion
of the heterologous gene or genes to be expressed; a wild type
baculovirus with a sequence homologous to the baculovirus-specific
fragment in the transfer vector (this allows for the homologous
recombination of the heterologous gene in to the baculovirus
genome); and appropriate insect host cells and growth media.
[0038] After inserting the DNA sequence encoding the protein into
the transfer vector, the vector and the wild type viral genome are
transfected into an insect host cell where the vector and viral
genome are allowed to recombine. The packaged recombinant virus is
expressed and recombinant plaques are identified and purified.
Materials and methods for baculovirus/insect cell expression
systems are commercially available in kit form from, inter alia,
Invitrogen, San Diego Calif. ("MaxBac" kit). These techniques are
generally known to those skilled in the art and fully described in
Summers and Smith, Texas Agricultural Experiment Station Bulletin
No. 1555 (1987) (hereinafter "Summers and Smith").
[0039] Prior to inserting the DNA sequence encoding the protein
into the baculovirus genome, the above described components,
comprising a promoter, leader (if desired), coding sequence of
interest, and transcription termination sequence, are usually
assembled into an intermediate transplacement construct (transfer
vector). This construct may contain a single gene and operably
linked regulatory elements; multiple genes, each with its owned set
of operably linked regulatory elements; or multiple genes,
regulated by the same set of regulatory elements. Intermediate
transplacement constructs are often maintained in a replicon, such
as an extrachromosomal element (e.g., plasmids) capable of stable
maintenance in a host, such as a bacterium. The replicon will have
a replication system, thus allowing it to be maintained in a
suitable host for cloning and amplification.
[0040] Currently, the most commonly used transfer vector for
introducing foreign genes into AcNPV is pAc373. Many other vectors,
known to those of skill in the art, have also been designed. These
include, for example, pVL985 (which alters the polyhedrin start
codon from ATG to ATT, and which introduces a BamHI cloning site 32
basepairs downstream from the ATT; see Luckow and Summers, Virology
(1989) 17:31.
[0041] The plasmid usually also contains the polyhedrin
polyadenylation signal (Miller et al. (1988) Ann. Rev. Microbiol.,
42:177) and a prokaryotic ampicillin-resistance (amp) gene and
origin of replication for selection and propagation in E. coli.
[0042] Baculovirus transfer vectors usually contain a baculovirus
promoter. A baculovirus promoter is any DNA sequence capable of
binding a baculovirus RNA polymerase and initiating the downstream
(5' to 3') transcription of a coding sequence (e.g. structural
gene) into mRNA. A promoter will have a transcription initiation
region which is usually placed proximal to the 5' end of the coding
sequence. This transcription initiation region usually includes an
RNA polymerase binding site and a transcription initiation site. A
baculovirus transfer vector may also have a second domain called an
enhancer, which, if present, is usually distal to the structural
gene. Expression may be either regulated or constitutive.
[0043] Structural genes, abundantly transcribed at late times in a
viral infection cycle, provide particularly useful promoter
sequences. Examples include sequences derived from the gene
encoding the viral polyhedron protein, Friesen et al., (1986) "The
Regulation of Baculovirus Gene Expression," in: The Molecular
Biology of Baculoviruses (ed. Walter Doerfler); EPO Publ. Nos. 127
839 and 155 476; and the gene encoding the p10 protein, Vlak et
al., (1988), J. Gen. Virol. 69:765.
[0044] DNA encoding suitable signal sequences can be derived from
genes for secreted insect or baculovirus proteins, such as the
baculovirus polyhedrin gene (Carbonell et al. (1988) Gene, 73:409).
Alternatively, since the signals for mammalian cell
posttranslational modifications (such as signal peptide cleavage,
proteolytic cleavage, and phosphorylation) appear to be recognised
by insect cells, and the signals required for secretion and nuclear
accumulation also appear to be conserved between the invertebrate
cells and vertebrate cells, leaders of non-insect origin, such as
those derived from genes encoding human .gamma.-interferon, Maeda
et al., (1985), Nature 315:592; human gastrin-releasing peptide,
Lebacq-Verheyden et al., (1988), Molec. Cell. Biol. 8:3129; human
IL-2, Smith et al., (1985) Proc. Nat'l Acad. Sci. USA, 82:8404;
mouse IL-3, (Miyajima et al., (1987) Gene 58:273; and human
glucocerebrosidase, Martin et al. (1988) DNA, 7:99, can also be
used to provide for secretion in insects.
[0045] A recombinant polypeptide or polyprotein may be expressed
intracellularly or, if it is expressed with the proper regulatory
sequences, it can be secreted. Good intracellular expression of
non-fused foreign proteins usually requires heterologous genes that
ideally have a short leader sequence containing suitable
translation initiation signals preceding an ATG start signal. If
desired, methionine at the N-terminus may be cleaved from the
mature protein by in vitro incubation with cyanogen bromide.
[0046] Alternatively, recombinant polyproteins or proteins which
are not naturally secreted can be secreted from the insect cell by
creating chimeric DNA molecules that encode a fusion protein
comprised of a leader sequence fragment that provides for secretion
of the foreign protein in insects. The leader sequence fragment
usually encodes a signal peptide comprised of hydrophobic amino
acids which direct the translocation of the protein into the
endoplasmic reticulum.
[0047] After insertion of the DNA sequence and/or the gene encoding
the expression product precursor of the protein, an insect cell
host is co-transformed with the heterologous DNA of the transfer
vector and the genomic DNA of wild type baculovirus--usually by
co-transfection. The promoter and transcription termination
sequence of the construct will usually comprise a 2-5 kb section of
the baculovirus genome. Methods for introducing heterologous DNA
into the desired site in the baculovirus virus are known in the
art. (See Summers and Smith supra; Ju et al. (1987); Smith et al.,
Mol. Cell. Biol. (1983) 3:2156; and Luckow and Summers (1989)). For
example, the insertion can be into a gene such as the polyhedrin
gene, by homologous double crossover recombination; insertion can
also be into a restriction enzyme site engineered into the desired
baculovirus gene. Miller et al., (1989), Bioessays 4:91. The DNA
sequence, when cloned in place of the polyhedrin gene in the
expression vector, is flanked both 5' and 3' by polyhedrin-specific
sequences and is positioned downstream of the polyhedrin
promoter.
[0048] The newly formed baculovirus expression vector is
subsequently packaged into an infectious recombinant baculovirus.
Homologous recombination occurs at low frequency (between about 1%
and about 5%); thus, the majority of the virus produced after
cotransfection is still wild-type virus. Therefore, a method is
necessary to identify recombinant viruses. An advantage of the
expression system is a visual screen allowing recombinant viruses
to be distinguished. The polyhedrin protein, which is produced by
the native virus, is produced at very high levels in the nuclei of
infected cells at late times after viral infection. Accumulated
polyhedrin protein forms occlusion bodies that also contain
embedded particles. These occlusion bodies, up to 15 .quadrature.m
in size, are highly refractile, giving them a bright shiny
appearance that is readily visualised under the light microscope.
Cells infected with recombinant viruses lack occlusion bodies. To
distinguish recombinant virus from wild-type virus, the
transfection supernatant is plagued onto a monolayer of insect
cells by techniques known to those skilled in the art. Namely, the
plaques are screened under the light microscope for the presence
(indicative of wild-type virus) or absence (indicative of
recombinant virus) of occlusion bodies. "Current Protocols in
Microbiology" Vol. 2 (Ausubel et al. eds) at 16.8 (Supp. 10, 1990);
Summers and Smith, supra; Miller et al. (1989).
[0049] Recombinant baculovirus expression vectors have been
developed for infection into several insect cells. For example,
recombinant baculoviruses have been developed for, inter alia:
Aedes aegypti, Autographa californica, Bombyx mori, Drosophila
melanogaster, Spodoptera frugiperda, and Trichoplusia ni (PCT Pub.
No. WO 89/046699; Carbonell et al., (1985) J. Virol. 56:153; Wright
(1986) Nature 321:718; Smith et al., (1983) Mol. Cell. Biol.
3:2156; and see generally, Fraser, et al. (1989) In Vitro Cell.
Dev. Biol. 25:225).
[0050] Cells and cell culture media are commercially available for
both direct and fusion expression of heterologous polypeptides in a
baculovirus/expression system; cell culture technology is generally
known to those skilled in the art. See, e.g., Summers and Smith
supra.
[0051] The modified insect cells may then be grown in an
appropriate nutrient medium, which allows for stable maintenance of
the plasmid(s) present in the modified insect host. Where the
expression product gene is under inducible control, the host may be
grown to high density, and expression induced. Alternatively, where
expression is constitutive, the product will be continuously
expressed into the medium and the nutrient medium must be
continuously circulated, while removing the product of interest and
augmenting depleted nutrients. The product may be purified by such
techniques as chromatography, e.g., HPLC, affinity chromatography,
ion exchange chromatography, etc.; electrophoresis; density
gradient centrifugation; solvent extraction, or the like. As
appropriate, the product may be further purified, as required, so
as to remove substantially any insect proteins which are also
secreted in the medium or result from lysis of insect cells, so as
to provide a product which is at least substantially free of host
debris, e.g., proteins, lipids and polysaccharides.
[0052] In order to obtain protein expression, recombinant host
cells derived from the transformants are incubated under conditions
which allow expression of the recombinant protein encoding
sequence. These conditions will vary, dependent upon the host cell
selected. However, the conditions are readily ascertainable to
those of ordinary skill in the art, based upon what is known in the
art.
[0053] Bacterial expression techniques are known in the art. A
bacterial promoter is any DNA sequence capable of binding bacterial
RNA polymerase and initiating the downstream (3'') transcription of
a coding sequence (e.g. structural gene) into mRNA. A promoter will
have a transcription initiation region which is usually placed
proximal to the 5' end of the coding sequence. This transcription
initiation region usually includes an RNA polymerase binding site
and a transcription initiation site. A bacterial promoter may also
have a second domain called an operator, that may overlap an
adjacent RNA polymerase binding site at which RNA synthesis begins.
The operator permits negative regulated (inducible) transcription,
as a gene repressor protein may bind the operator and thereby
inhibit transcription of a specific gene. Constitutive expression
may occur in the absence of negative regulatory elements, such as
the operator. In addition, positive regulation may be achieved by a
gene activator protein binding sequence, which, if present is
usually proximal (5') to the RNA polymerase binding sequence. An
example of a gene activator protein is the catabolite activator
protein (CAP), which helps initiate transcription of the lac operon
in Escherichia coli (E. coli) [Raibaud et al. (1984) Annu. Rev.
Genet. 18:173]. Regulated expression may therefore be either
positive or negative, thereby either enhancing or reducing
transcription.
[0054] Sequences encoding metabolic pathway enzymes provide
particularly useful promoter sequences. Examples include promoter
sequences derived from sugar metabolising enzymes, such as
galactose, lactose (lac) [Chang et al. (1977) Nature 198:1056], and
maltose. Additional examples include promoter sequences derived
from biosynthetic enzymes such as tryptophan (trp) [Goeddel et al.
(1980) Nuc. Acids Res. 8:4057; Yelverton et al. (1981) Nucl. Acids
Res. 9:731; U.S. Pat. No. 4,738,921; EPO Publ. Nos. 036 776 and 121
775]. The g-laotamase (bla) promoter system [Weissmann (1981) "The
cloning of interferon and other mistakes." In Interferon 3 (ed. I.
Gresser)], bacteriophage lambda PL [Shimatake et al. (1981) Nature
292:128] and T5 [U.S. Pat. No. 4,689,406] promoter systems also
provide useful promoter sequences.
[0055] In addition, synthetic promoters that do not occur in nature
also function as bacterial promoters. For example, transcription
activation sequences of one bacterial or bacteriophage promoter may
be joined with the operon sequences of another bacterial or
bacteriophage promoter, creating a synthetic hybrid promoter [U.S.
Pat. No. 4,551,433]. For example, the tac promoter is a hybrid
trp-lac promoter comprised of both trp promoter and lac operon
sequences that is regulated by the lac repressor [Amann et al.
(1983) Gene 25:167; de Boer et al. (1983) Proc. Natl. Acad. Sci.
80:21]. Furthermore, a bacterial promoter can include naturally
occurring promoters of non-bacterial origin that have the ability
to bind bacterial RNA polymerase and initiate transcription. A
naturally occurring promoter of non-bacterial origin can also be
coupled with a compatible RNA polymerase to produce high levels of
expression of some genes in prokaryotes. The bacteriophage T7 RNA
polymerase/promoter system is an example of a coupled promoter
system [Studier et al. (1986) J. Mol. Biol. 189:113; Tabor et al.
(1985) Proc Natl. Acad. Sci. 82:1074]. In addition, a hybrid
promoter can also be comprised of a bacteriophage promoter and an
E. coli operator region (EPO Publ. No. 267 851).
[0056] In addition to a functioning promoter sequence, an efficient
ribosome binding site is also useful for the expression of foreign
genes in prokaryotes. In E. coli, the ribosome binding site is
called the Shine-Dalgarno (SD) sequence and includes an initiation
codon (ATG) and a sequence 3-9 nucleotides in length located 3-11
nucleotides upstream of the initiation codon [Shine et al. (1975)
Nature 254:34]. The SD sequence is thought to promote binding of
mRNA to the ribosome by the pairing of bases between the SD
sequence and the 3' and of E. coli 16S rRNA [Steitz et al. (1979)
"Genetic signals and nucleotide sequences in messenger RNA." In
Biological Regulation and Development: Gene Expression (ed. R. F.
Goldberger)]. To express eukaryotic genes and prokaryotic genes
with weak ribosome-binding site [Sambrook et al. (1989) "Expression
of cloned genes in Escherichia coli." In Molecular Cloning: A
Laboratory Manual].
[0057] A DNA molecule may be expressed intracellularly. A promoter
sequence may be directly linked with the DNA molecule, in which
case the first amino acid at the N-terminus will always be a
methionine, which is encoded by the ATG start codon. If desired,
methionine at the N-terminus may be cleaved from the protein by in
vitro incubation with cyanogen bromide or by either in vivo on in
vitro incubation with a bacterial methionine N-terminal peptidase
(EPO Publ. No. 219 237).
[0058] Fusion proteins provide an alternative to direct expression.
Usually, a DNA sequence encoding the N-terminal portion of an
endogenous bacterial protein, or other stable protein, is fused to
the 5' end of heterologous coding sequences. Upon expression, this
construct will provide a fusion of the two amino acid sequences.
For example, the bacteriophage lambda cell gene can be linked at
the 5' terminus of a foreign gene and expressed in bacteria. The
resulting fusion protein preferably retains a site for a processing
enzyme (factor Xa) to cleave the bacteriophage protein from the
foreign gene [Nagai et al. (1984) Nature 309:810]. Fusion proteins
can also be made with sequences from the lacZ [Jia et al. (1987)
Gene 60:197], trpE [Allen et al. (1987) J. Biotechnol. 5:93; Makoff
et al. (1989) J. Gen. Microbiol. 135:11], and Chey [EPO Publ. No.
324 647] genes. The DNA sequence at the junction of the two amino
acid sequences may or may not encode a cleavable site. Another
example is a ubiquitin fusion protein. Such a fusion protein is
made with the ubiquitin region that preferably retains a site for a
processing enzyme (e.g. ubiquitin specific processing-protease) to
cleave the ubiquitin from the foreign protein. Through this method,
native foreign protein can be isolated [Miller et al. (1989)
Bio/Technology 7:698].
[0059] Alternatively, foreign proteins can also be secreted from
the cell by creating chimeric DNA molecules that encode a fusion
protein comprised of a signal peptide sequence fragment that
provides for secretion of the foreign protein in bacteria [U.S.
Pat. No. 4,336,336]. The signal sequence fragment usually encodes a
signal peptide comprised of hydrophobic amino acids which direct
the secretion of the protein from the cell. The protein is either
secreted into the growth media (gram-positive bacteria) or into the
periplasmic space, located between the inner and outer membrane of
the cell (gram-negative bacteria). Preferably there are processing
sites, which can be cleaved either in vivo or in vitro encoded
between the signal peptide fragment and the foreign gene.
[0060] DNA encoding suitable signal sequences can be derived from
genes for secreted bacterial proteins, such as the E. coli outer
membrane protein gene (ompA) [Masui et al. (1983), in: Experimental
Manipulation of Gene Expression; Ghrayeb et al. (1984) EMBO J.
3:2437] and the E. coli alkaline phosphatase signal sequence (phoA)
[Oka et al. (1985) Proc. Natl. Acad. Sci. 82:7212]. As an
additional example, the signal sequence of the alpha-amylase gene
from various Bacillus strains can be used to secrete heterologous
proteins from B. subtilis [Palva et al. (1982) Proc. Natl. Acad.
Sci. USA 79:5582; EPO Publ. No. 244 042].
[0061] Usually, transcription termination sequences recognised by
bacteria are regulatory regions located 3' to the translation stop
codon, and thus together with the promoter flank the coding
sequence. These sequences direct the transcription of an mRNA which
can be translated into the polypeptide encoded by the DNA.
Transcription termination sequences frequently include DNA
sequences of about 50 nucleotides capable of forming stem loop
structures that aid in terminating transcription. Examples include
transcription termination sequences derived from genes with strong
promoters, such as the trp gene in E. coli as well as other
biosynthetic genes.
[0062] Usually, the above described components, comprising a
promoter, signal sequence (if desired), coding sequence of
interest, and transcription termination sequence, are put together
into expression constructs. Expression constructs are often
maintained in a replicon, such as an extrachromosomal element
(e.g., plasmids) capable of stable maintenance in a host, such as
bacteria. The replicon will have a replication system, thus
allowing it to be maintained in a prokaryotic host either for
expression or for cloning and amplification. In addition, a
replicon may be either a high or low copy number plasmid. A high
copy number plasmid will generally have a copy number ranging from
about 5 to about 200, and usually about 10 to about 150. A host
containing a high copy number plasmid will preferably contain at
least about 10, and more preferably at least about 20 plasmids.
Either a high or low copy number vector may be selected, depending
upon the effect of the vector and the foreign protein on the
host.
[0063] Alternatively, the expression constructs can be integrated
into the bacterial genome with an integrating vector. Integrating
vectors usually contain at least one sequence homologous to the
bacterial chromosome that allows the vector to integrate.
Integrations appear to result from recombinations between
homologous DNA in the vector and the bacterial chromosome. For
example, integrating vectors constructed with DNA from various
Bacillus strains integrate into the Bacillus chromosome (EPO Publ.
No. 127 328). Integrating vectors may also be comprised of
bacteriophage or transposon sequences.
[0064] Usually, extrachromosomal and integrating expression
constructs may contain selectable markers to allow for the
selection of bacterial strains that have been transformed.
Selectable markers can be expressed in the bacterial host and may
include genes which render bacteria resistant to drugs such as
ampicillin, chloramphenicol, erythromycin, kanamycin (neomycin),
and tetracycline [Davies et al. (1978) Annu. Rev. Microbiol.
32:469]. Selectable markers may also include biosynthetic genes,
such as those in the histidine, tryptophan, and leucine
biosynthetic pathways.
[0065] Alternatively, some of the above described components can be
put together in transformation vectors. Transformation vectors are
usually comprised of a selectable market that is either maintained
in a replicon or developed into an integrating vector, as described
above.
[0066] Expression and transformation vectors, either
extra-chromosomal replicons or integrating vectors, have been
developed for transformation into many bacteria. For example,
expression vectors have been developed for, inter alia, the
following bacteria: Bacillus subtilis [Palva et al. (1982) Proc.
Natl. Acad. Sci. USA 79:5582; EPO Publ. Nos. 036 259 and 063 953;
PCT Publ. No. WO 84/04541], Escherichia coli [Shimatake et al.
(1981) Nature 292:128; Amann et al. (1985) Gene 40:183; Studier et
al. (1986) J. Mol. Biol. 189:113; EPO Publ. Nos. 036 776, 136 829
and 136 907], Streptococcus cremoris [Powell et al. (1988) Appl.
Environ. Microbiol. 54:655]; Streptococcus lividans [Powell et al.
(1988) Appl. Environ. Microbiol. 54:655], Streptomyces lividans
[U.S. Pat. No. 4,745,056].
[0067] Methods of introducing exogenous DNA into bacterial hosts
are well-known in the art, and usually include either the
transformation of bacteria treated with CaCl.sub.2 or other agents,
such as divalent cations and DMSO. DNA can also be introduced into
bacterial cells by electroporation. Transformation procedures
usually vary with the bacterial species to be transformed. See
e.g., [Masson et al. (1989) FEMS Microbiol. Lett. 60:273; Palva et
al. (1982) Proc. Natl. Acad. Sci. USA 79:5582; EPO Publ. Nos. 036
259 and 063 953; PCT Publ. No. WO 84/04541, Bacillus], [Miller et
al. (1988) Proc. Natl. Acad. Sci. 85:856; Wang et al. (1990) J.
Bacteriol. 172:949, Campylobacter], [Cohen et al. (1973) Proc.
Natl. Acad. Sci. 69:2110; Dower et al. (1988) Nucleic Acids Res.
16:6127; Kushner (1978) "An improved method for transformation of
Escherichia coli with ColE1-derived plasmids. In Genetic
Engineering: Proceedings of the International Symposium on Genetic
Engineering (eds. H. W. Boyer and S. Nicosia); Mandel et al. (1970)
J. Mol. Biol. 53:159; Taketo (1988) Biochim. Biophys. Acta 949:318;
Escherichia], [Chassy et al. (1987) FEMS Microbiol. Lett. 44:173
Lactobacillus]; [Fiedler et al. (1988) Anal. Biochem 170:38,
Pseudomonas]; [Augustin et al. (1990) FEMS Microbiol. Lett. 66:203,
Staphylococcus], [Barany et al. (1980) J. Bacteriol. 144:698;
Harlander (1987) "Transformation of Streptococcus lactis by
electroporation, in: Streptococcal Genetics (ed. J. Ferretti and R.
Curtiss III); Perry et al. (1981) Infect. Immun. 32:1295; Powell et
al. (1988) Appl. Environ. Microbiol. 54:655; Somkuti et al. (1987)
Proc. 4th Evr. Cong. Biotechnology 1:412, Streptococcus].
[0068] Yeast expression systems are also known to one of ordinary
skill in the art. A yeast promoter is any DNA sequence capable of
binding yeast RNA polymerase and initiating the downstream (3')
transcription of a coding sequence (e.g. structural gene) into
mRNA. A promoter will have a transcription initiation region which
is usually placed proximal to the 5' end of the coding sequence.
This transcription initiation region usually includes an RNA
polymerase binding site (the "TATA Box") and a transcription
initiation site. A yeast promoter may also have a second domain
called an upstream activator sequence (UAS), which, if present, is
usually distal to the structural gene. The UAS permits regulated
(inducible) expression. Constitutive expression occurs in the
absence of a UAS. Regulated expression may be either positive or
negative, thereby either enhancing or reducing transcription.
[0069] Yeast is a fermenting organism with an active metabolic
pathway, therefore sequences encoding enzymes in the metabolic
pathway provide particularly useful promoter sequences. Examples
include alcohol dehydrogenase (ADH) (EPO Publ. No. 284 044),
enolase, glucokinase, glucose-6-phosphate isomerase,
glyceraldehyde-3-phosphate-dehydrogenase (GAP or GAPDH),
hexokinase, phosphofructokinase, 3-phosphoglycerate mutase, and
pyruvate kinase (PyK) (EPO Publ. No. 329 203). The yeast PHO5 gene,
encoding acid phosphatase, also provides useful promoter sequences
[Myanohara et al. (1983) Proc. Natl. Acad. Sci. USA 80:1].
[0070] In addition, synthetic promoters which do not occur in
nature also function as yeast promoters. For example, UAS sequences
of one yeast promoter may be joined with the transcription
activation region of another yeast promoter, creating a synthetic
hybrid promoter. Examples of such hybrid promoters include the ADH
regulatory sequence linked to the GAP transcription activation
region (U.S. Pat. Nos. 4,876,197 and 4,880,734). Other examples of
hybrid promoters include promoters which consist of the regulatory
sequences of either the ADH2, GAL4, GAL10, OR PHO5 genes, combined
with the transcriptional activation region of a glycolytic enzyme
gene such as GAP or PyK (EPO Publ. No. 164 556). Furthermore, a
yeast promoter can include naturally occurring promoters of
non-yeast origin that have the ability to bind yeast RNA polymerase
and initiate transcription. Examples of such promoters include,
inter alia, [Cohen et al. (1980) Proc. Natl. Acad. Sci. USA
77:1078; Henikoff et al. (1981) Nature 283:835; Hollenberg et al.
(1981) Curr. Topics Microbiol. Immunol. 96:119; Hollenberg et al.
(1979) "The Expression of Bacterial Antibiotic Resistance Genes in
the Yeast Saccharomyces cerevisiae," in: Plasmids of Medical,
Environmental and Commercial Importance (eds. K. N. Timmis and A.
Puhler); Mercerau-Puigalon et al. (1980) Gene 11:163; Panthier et
al. (1980) Curr. Genet. 2:109;].
[0071] A DNA molecule may be expressed intracellularly in yeast. A
promoter sequence may be directly linked with the DNA molecule, in
which case the first amino acid at the N-terminus of the
recombinant protein will always be a methionine, which is encoded
by the ATG start codon. If desired, methionine at the N-terminus
may be cleaved from the protein by in vitro incubation with
cyanogen bromide.
[0072] Fusion proteins provide an alternative for yeast expression
systems, as well as in mammalian, baculovirus, and bacterial
expression systems. Usually, a DNA sequence encoding the N-terminal
portion of an endogenous yeast protein, or other stable protein, is
fused to the 5' end of heterologous coding sequences. Upon
expression, this construct will provide a fusion of the two amino
acid sequences. For example, the yeast or human superoxide
dismutase (SOD) gene, can be linked at the 5' terminus of a foreign
gene and expressed in yeast. The DNA sequence at the junction of
the two amino acid sequences may or may not encode a cleavable
site. See e.g., EPO Publ. No. 196 056. Another example is a
ubiquitin fusion protein. Such a fusion protein is made with the
ubiquitin region that preferably retains a site for a processing
enzyme (e.g. ubiquitin-specific processing protease) to cleave the
ubiquitin from the foreign protein. Through this method, therefore,
native foreign protein can be isolated (eg. WO88/024066).
[0073] Alternatively, foreign proteins can also be secreted from
the cell into the growth media by creating chimeric DNA molecules
that encode a fusion protein comprised of a leader sequence
fragment that provide for secretion in yeast of the foreign
protein. Preferably, there are processing sites encoded between the
leader fragment and the foreign gene that can be cleaved either in
vivo or in vitro. The leader sequence fragment usually encodes a
signal peptide comprised of hydrophobic amino acids which direct
the secretion of the protein from the cell.
[0074] DNA encoding suitable signal sequences can be derived from
genes for secreted yeast proteins, such as the yeast invertase gene
(EPO Publ. No. 012 873; JPO Publ. No. 62,096,086) and the A-factor
gene (U.S. Pat. No. 4,588,684). Alternatively; leaders of non-yeast
origin, such as an interferon leader, exist that also provide for
secretion in yeast (EPO Publ. No. 060 057).
[0075] A preferred class of secretion leaders are those that employ
a fragment of the yeast alpha-factor gene, which contains both a
"pre" signal sequence, and a "pro" region. The types of
alpha-factor fragments that can be employed include the full-length
pre-pro alpha factor leader (about 83 amino acid residues) as well
as truncated alpha-factor leaders (usually about 25 to about 50
amino acid residues) (U.S. Pat. Nos. 4,546,083 and 4,870,008; EPO
Publ. No. 324 274). Additional leaders employing an alpha-factor
leader fragment that provides for secretion include hybrid
alpha-factor leaders made with a presequence of a first yeast, but
a pro-region from a second yeast alphafactor. (See e.g., PCT Publ.
No. WO 89/02463.)
[0076] Usually, transcription termination sequences recognised by
yeast are regulatory regions located 3' to the translation stop
codon, and thus together with the promoter flank the coding
sequence. These sequences direct the transcription of an mRNA which
can be translated into the polypeptide encoded by the DNA. Examples
of transcription terminator sequence and other yeast-recognised
termination sequences, such as those coding for glycolytic
enzymes.
[0077] Usually, the above described components, comprising a
promoter, leader (if desired), coding sequence of interest, and
transcription termination sequence, are put together into
expression constructs. Expression constructs are often maintained
in a replicon, such as an extrachromosomal element (e.g., plasmids)
capable of stable maintenance in a host, such as yeast or bacteria.
The replicon may have two replication systems, thus allowing it to
be maintained, for example, in yeast for expression and in a
prokaryotic host for cloning and amplification. Examples of such
yeast-bacteria shuttle vectors include YEp24 [Botstein et al.
(1979) Gene 8:17-24], pCl/1 [Brake et al. (1984) Proc. Natl. Acad.
Sci USA 81:4642-4646], and YRp17 [Stinchcomb et al. (1982) J. Mol.
Biol. 158:157]. In addition, a replicon may be either a high or low
copy number plasmid. A high copy number plasmid will generally have
a copy number ranging from about 5 to about 200, and usually about
10 to about 150. A host containing a high copy number plasmid will
preferably have at least about 10, and more preferably at least
about 20. Enter a high or low copy number vector may be selected,
depending upon the effect of the vector and the foreign protein on
the host. See e.g., Brake et al., supra.
[0078] Alternatively, the expression constructs can be integrated
into the yeast genome with an integrating vector. Integrating
vectors usually contain at least one sequence homologous to a yeast
chromosome that allows the vector to integrate, and preferably
contain two homologous sequences flanking the expression construct.
Integrations appear to result from recombinations between
homologous DNA in the vector and the yeast chromosome [Orr-Weaver
et al. (1983) Methods in Enzymol. 101:228-245]. An integrating
vector may be directed to a specific locus in yeast by selecting
the appropriate homologous sequence for inclusion in the vector.
See Orr-Weaver et al., supra. One or more expression construct may
integrate, possibly affecting levels of recombinant protein
produced [Rine et al. (1983) Proc. Natl. Acad. Sci. USA 80:6750].
The chromosomal sequences included in the vector can occur either
as a single segment in the vector, which results in the integration
of the entire vector, or two segments homologous to adjacent
segments in the chromosome and flanking the expression construct in
the vector, which can result in the stable integration of only the
expression construct.
[0079] Usually, extrachromosomal and integrating expression
constructs may contain selectable markers to allow for the
selection of yeast strains that have been transformed. Selectable
markers may include biosynthetic genes that can be expressed in the
yeast host, such as ADE2, HIS4, LEU2, TRP1, and ALG7, and the G418
resistance gene, which confer resistance in yeast cells to
tunicamycin and G418, respectively. In addition, a suitable
selectable marker may also provide yeast with the ability to grow
in the presence of toxic compounds, such as metal. For example, the
presence of CUP1 allows yeast to grow in the presence of copper
ions [Butt et al. (1987) Microbiol, Rev. 51:351].
[0080] Alternatively, some of the above described components can be
put together into transformation vectors. Transformation vectors
are usually comprised of a selectable marker that is either
maintained in a replicon or developed into an integrating vector,
as described above.
[0081] Expression and transformation vectors, either
extrachromosomal replicons or integrating vectors, have been
developed for transformation into many yeasts. For example,
expression vectors have been developed for, inter alia, the
following yeasts: Candida albicans [Kurtz, et al. (1986) Mol. Cell.
Biol. 6:142], Candida maltosa [Kunze, et al. (1985) J. Basic
Microbiol. 25:141]. Hansenula polymorpha [Gleeson, et al. (1986) J.
Gen. Microbial. 132:3459; Roggenkamp et al. (1986) Mol. Gen. Genet.
202:302], Kluyveromyces fragilis [Das, et al. (1984) J. Bacteriol.
158:1165], Kluyveromyces lactis [De Louvencourt et al. (1983) J.
Bacteriol. 154:737; Van den Berg et al. (1990) Bio/Technology
8:135], Pichia guillerimondii [Kunze et al. (1985) J. Basic
Microbiol. 25:141], Pichia pastoris [Cregg, et al. (1985) Mol.
Cell. Biol. 5:3376; U.S. Pat. Nos. 4,837,148 and 4,929,555],
Saccharomyces cerevisiae [Hinnen et al. (1978) Proc. Natl. Acad.
Sci. USA 75:1929; Ito et al. (1983) J. Bacteriol. 153:163],
Schizosaccharomyces pombe [Beach and Nurse (1981) Nature 300:706],
and Yarrowia lipolytica [Davidow, et al. (1985) Curr. Genet.
10:380471 Gaillardin, et al. (1985) Curr. Genet. 10:49].
[0082] Methods of introducing exogenous DNA into yeast hosts are
well-known in the art, and usually include either the
transformation of spheroplasts or of intact yeast cells treated
with alkali cations. Transformation procedures usually vary with
the yeast species to be transformed. See e.g., [Kurtz et al. (1986)
Mot Cell. Biol. 6:142; Kunze et al. (1985) J. Basic Microbiol.
25:141; Candida]; [Gleeson et al. (1986) J. Gen. Microbiol.
132:3459; Roggenkamp et al. (1986) Mol. Gen. Genet. 202:302;
Hansenula]; [Das et al. (1984) J. Bacteriol. 158:1165; De
Louvencourt et al. (1983) J. Bacteriol. 154:1165; Van den Berg et
al. (1990) Bio/Technology 8:135; Kluyveromyces]; [Cregg et al.
(1985) Mol. Cell. Biol. 5:3376; Kunze et al. (1985) J. Basic.
Microbiol. 25:141; U.S. Pat. Nos. 4,837,148 and 4,929,555; Pichia];
[Hinnen et al. (1978) Proc. Natl. Acad. Sci. USA 75; 1929; Ito et
al. (1983) J. Bacteriol. 153:163 Saccharomyces]; [Beach and Nurse
(1981) Nature 300:706; Schizosaccharomyces]; [Davidow et al. (1985)
CWT. Genet. 10:39; Gaillardin et al. (1985) Curr. Genet. 10:49;
Yarrowia].
[0083] Methods for the isolation and purification of recombinant
proteins will be well known to those of skill in the art and are
summarised, for example in Sambrook et al (1989). Particularly in
bacteria such as E. coli, the recombinant protein will form
inclusion bodies within the bacterial cell, thus facilitating its
preparation. If produced in inclusion bodies, the carrier protein
may need to be refolded to its natural conformation. Methods for
renaturing proteins to their natural folded state are well known in
the art.
[0084] Species in which the carrier proteins of the present
invention may be immunogenic and thus effective in eliciting an
immune response include all mammals, especially humans. In most
cases, it will be preferred that the carrier proteins of the
present invention are active eliciting an immune response in
humans. The population of humans that are in greatest need of
protection from disease caused by encapsulated bacteria are infants
of between approximately 3 months and 2 years of age. It is during
this period that the infants generally do not receive protection
from mothers' milk and do not yet possess a sufficiently
well-developed immune system themselves to generate an immune
response against polysaccharide antigens.
[0085] According to a further aspect of the present invention,
there are also provided nucleic acid molecules encoding carrier
proteins according to the first aspect of the invention. As will be
apparent to the skilled artisan, such nucleic acid molecules will
be designed using the genetic code so as to encode the epitope that
is desired.
[0086] Additionally, in order to precisely tailor the exact
properties of the encoded carrier proteins, the skilled artisan
will appreciate that changes may be made at the nucleotide level
from known epitope sequences, by addition, substitution, deletion
or insertion of one or more nucleotides. Site-directed mutagenesis.
(SDM) is the method of preference used to generate mutated carrier
proteins according to the present invention. There are many
techniques of SDM now known to the skilled artisan, including
oligonucleotide-directed mutagenesis using PCR as set out for
example by Sambrook et al., (1989) or using commercially available
kits.
[0087] Most carrier proteins produced by such techniques of
mutagenesis will be less efficacious than wild type proteins.
However, it may be that in a minority of cases, such changes
produce molecules with improved carrier protein function as
desired, such as greater immunogenicity in a certain organism.
[0088] The nucleic acid molecules according to this aspect of the
present invention may comprise DNA, RNA or cDNA and may
additionally comprise nucleotide analogues in the coding sequence.
Preferably, the nucleic acid molecules will comprise DNA.
[0089] A further aspect of the present invention provides a host
cell containing a nucleic acid encoding a carrier protein. A still
further aspect provides a method comprising introducing the
encoding nucleic acid into a host cell or organism. Introduction of
nucleic acid may employ any available technique. In eukaryotic
cells, suitable techniques may include calcium phosphate
transfection, DNA-dextran, electroporation, liposome-mediated
transfection or transduction using retrovirus or other viruses such
as vaccinia. In bacterial cells, suitable techniques may include
calcium chloride transformation, electroporation or transfection
using bacteriophage. Introduction of the nucleic acid may be
followed by causing or allowing expression from the nucleic acid,
for example by culturing host cells under conditions for allowing
expression of the gene.
[0090] In one embodiment, the nucleic acid is integrated into the
genome of the host cell. Integration may be promoted by the
inclusion of sequences that promote recombination with the genome,
in accordance with standard techniques (see Sambrook et al.,
1989).
[0091] According to a further embodiment of the present invention,
there is provided a carrier protein comprising at least five CD4+
T-cell epitopes, conjugated to polysaccharide. By polysaccharide is
meant any linear or branched polymer consisting of monosaccharide
residues, usually linked by glycosidic linkages, and thus includes
oligosaccharides. Preferably, the polysaccharide will contain
between 2 and 50 monosaccharide unites, more preferably between 6
and 30 monosaccharide units.
[0092] The polysaccharide component may be based on or derived from
polysaccharide components of the polysaccharide capsule from many
Gram positive and Gram negative bacterial pathogens such as H.
influenzae, N. meningitidis and S. pneumoniae. This capsule
represents a major virulence factor that is important for
nasopharyngeal colonisation and systemic invasion. Other bacteria
from which polysaccharide components may be conjugated to the
carrier proteins of the present invention include Staphylococcus
aureus, Klebsiella, Pseudomonas, Salmonella typhi, Pseudomonas
aeruginosa, and Shigella dysenteriae. Polysaccharide components
suitable for use according to this aspect of the present invention
include the Hib oligosaccharide, lipopolysaccharide from
Pseudomonas aeruginosa (Seid and Sadoff, 1981), lipopolysaccharides
from Salmonella (Konadu et al., 1996) and the O-specific
polysaccharide from Shigella dysenteriae (Chu et al, 1991). Other
polysaccharide components suitable for use in accordance with the
present invention will be well-known to those of skill in the
art.
[0093] Fragments of bacterial capsular polysaccharide may be
produced by any suitable method, such as by acid hydrolysis or
ultrasonic irradiation (Szn et al, 1986). Other methods of
preparation of the polysaccharide components will be well known to
those of skill in the art.
[0094] The polysaccharide component of the conjugate vaccine should
preferably be coupled to the carrier protein by a covalent linkage.
A particularly preferred method of coupling polysaccharide and
protein is by reductive amination. Other methods include:
activation of the polysaccharide with cyanogen bromide followed by
reaction with adipic acid dihydrazide (spacer) and by conjugation
to carboxide groups of carrier protein using soluble carbodiimides
(Shneerson et al, 1986); functionalisation of the carrier protein
with adipic acid dihydrazide followed by coupling to cyanogen
bromide activated polysaccharides (Dick et al, 1989); chemical
modification of both the carrier protein and the polysaccharide
followed by their coupling (Marburg et al, 1986; Marburg et al,
1987 and 1989). In some cases, polysaccharides containing carboxide
groups such as group C meningococcal polysaccharides can be
directly conjugated to proteins using soluble carbodiimides.
Polysaccharides can also be activated using alternative agents such
as CDAP (1-cyano-4-dimethylamino-pyrridinium tetrafluorborate) and
then directly conjugated to the carrier protein (Konadu et al,
1996). Periodate-treated polysaccharides or oligosaccharides can
all be conjugated to proteins by means of reductive amination
(Jennings and Lugowsky, 1982; Anderson, 1983; Insel, 1986).
Alternatively, oligosaccharides obtained by acidic hydrolysis can
be chemically derivatised by introducing into their reducing end
groups an hydrocarbon spacer bearing an active ester terminus; this
activated oligosaccharide can be conjugated to the selected carrier
protein (Costantino et al, 1992).
[0095] The polysaccharide molecule may be coupled to the carrier
protein by a spacer molecule, such as adipic acid. This spacer
molecule can be used to facilitate the coupling of protein to
polysaccharide. After the coupling reaction has been performed, the
conjugate may be purified by diafiltration or other known methods
to remove unreacted protein or polysaccharide components.
[0096] According to a further aspect of the present invention there
is provided a method of production of a carrier protein according
to the first aspect of the present invention, comprising the steps
of: [0097] (a) constructing oligonucleotide molecules that encode
peptide epitopes; [0098] (b) annealing the oligonucleotide
molecules to form duplexes; [0099] (c) introducing the
oligonucleotide duplexes into an expression vector so as to encode
a fusion protein; [0100] (d) introducing the expression vector into
a bacterial host cell to allow expression of the fusion protein;
[0101] (e) isolating the fusion protein produced from a culture of
said bacteria.
[0102] Optionally, this method may additionally comprise
conjugating the carrier protein to a polysaccharide molecule.
[0103] Preferably, the bacterial host cell used in this method is
an E. coli bacterial host cell.
[0104] According to the further aspect of the present invention,
there is provided a composition comprising a carrier protein that
contains at least five CD4+ T-Cell epitopes conjugated to a
polysaccharide, in conjunction with a pharmaceutically acceptable
excipient. Such a composition may be rationally designed so as to
provide protection against disease caused by pathogenic bacteria
such as H. influenzae, S. pneumoniae, N. meningitidis,
Staphylococcus aureus, Klebsiella, Pseudomonas and S. typhi and
accordingly, may be used as a vaccine. Vaccines according to the
invention may either be prophylactic (ie. to prevent infection) or
therapeutic (ie. to treat disease after infection).
[0105] By pharmaceutically-acceptable excipient is meant any
compound that does not itself induce the production of antibodies
harmful to the individual receiving the composition. The excipient
should be suitable for oral, subcutaneous, intramuscular, topical
or intravenous administration. Suitable compounds are typically
large, slowly metabolised macromolecules such as proteins,
polysaccharides, polylactic acids, polyglycolic acids, polymeric
amino acids, amino acid copolymers, lipid aggregates (such as oil
droplets or liposomes) and inactive virus particles. Such compounds
are well known to those of skill in the art. Additionally, these
compounds may function as immunostimulating agents ("adjuvants").
Furthermore, the antigen may be conjugated to a bacterial
toxoid.
[0106] Preferred adjuvants to enhance effectiveness of the
composition include, but are not limited to: (1) aluminium salts
(alum), such as aluminium hydroxide, aluminium phosphate, aluminium
sulphate, etc; (2) oil-in-water emulsion formulations (with or
without other specific immunostimulating agents such as muramyl
peptides or bacterial cell wall components), such as for example
(a) MF59.TM. (WO 90/14837), containing 5% Squalene, 0.5% Tween.TM.
80, and 0.5% Span 85 (optionally containing various amounts, of
MTP-PE, although not required) formulated into submicron particles
using a microfluidizer (b) SAF, containing 10% Squalane, 0.4% Tween
80, 5% pluronic-blocked polymer L121, and thr-MDP either
microfluidised into a submicron emulsion or vortexed to generate a
larger particle size emulsion, and (c) Ribi.TM. adjuvant system
(RAS), containing 2% Squalene, 0.2% Tween 80, and one or more
bacterial cell wall components from the group consisting of
monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell
wall skeleton (CWS), preferably MPL+CWS (Detox.TM.); (3) saponin
adjuvants, such as Stimulon.TM. may be used or particles generated
therefrom such as ISCOMs (immunostimulating complexes); (4)
Freund's complete and incomplete adjuvants (CFA & IFA); (5)
cytokines, such as interleukins (eg. IL-1, IL-2, IL-4, IL-5, IL-6,
IL-7, IL-12, etc.), interferons (eg. IFN.gamma.), macrophage colony
stimulating factor (M-CSF), tumor necrosis factor (TNF), etc; and
(6) other substances that act as immunostimulating agents to
enhance the efficacy of the composition. Alum and MF59.TM. are
preferred.
[0107] As mentioned above, muramyl peptides include, but are not
limited to, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP),
N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP),
N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-s-
n-glycero-3-huydroxyphosphoryloxy)-ethylamine (MTP-PE), etc.
[0108] The immunogenic compositions (eg. the antigen,
pharmaceutically acceptable carrier, and adjuvant) typically will
contain diluents, such as water, saline, glycerol, ethanol, etc.
Additionally, auxiliary substances, such as wetting or emulsifying
agents, pH buffering substances, and the like, may be present in
such vehicles.
[0109] Typically, the immunogenic compositions are prepared as
injectables, either as liquid solutions or suspensions; solid forms
suitable for solution in, or suspension in, liquid vehicles prior
to injection may also be prepared. The preparation also may be
emulsified or encapsulated in liposomes for enhanced adjuvanticity
effect, as discussed above.
[0110] Immunogenic compositions used as vaccines comprise an
immunologically effective amount of the carrier protein, as well as
any other of the above-mentioned components, as needed. By
"immunologically effective amount", it is meant that the
administration of that amount to an individual, either in a single
dose or as part of a series, is effective for treatment or
prevention. This amount varies depending upon the health and
physical condition of the individual to be treated, the taxonomic
group of individual to be treated (eg. non-human primate, primate,
etc.), the capacity of the individual's immune system to synthesise
antibodies, the degree of protection desired, the formulation of
the vaccine, the treating doctor's assessment of the medical
situation, and other relevant factors. It is expected that the
amount will fall in a relatively broad range that can be determined
through routine trials.
[0111] The immunogenic compositions are conventionally administered
parenterally eg. by injection, either subcutaneously or
intramuscularly. They may also be administered to mucosal surfaces
(eg. oral or intranasal), or in the form of pulmonary formulations,
sup-positories, or transdermal applications. Dosage treatment may
be a single dose schedule or a multiple dose schedule. The vaccine
may be administered in conjunction with other immunoregulatory
agents.
[0112] As an alternative to protein-based vaccines, DNA vaccination
may be employed [eg. Robinson & Torres (1997) Seminars in
Immunology 9:271-283; Donnelly et al. (1997) Annu Rev Immunol
15:617-648]. Accordingly, rather than comprise a peptide,
oligopeptide, or polypeptide compound, the vaccines of the
invention might comprise nucleic acid encoding these compounds.
[0113] According to a further aspect of the invention, there is
provided a process for the formulation of an immunogenic
composition comprising bringing a carrier protein according to the
first aspect of the invention, conjugated to a polysaccharide, into
association with a pharmaceutically-acceptable carrier, optionally
with an adjuvant.
[0114] According to a still further aspect of the present
invention, there is provided a method of vaccinating a mammal,
preferably a human against a disease, comprising administering to
the mammal a composition of carrier protein conjugated to
polysaccharide, optionally with a pharmaceutically-acceptable
carrier such as an adjuvant.
[0115] Various aspects and embodiments of the present invention
will now be described in more detail by way of example, with
particular reference to the carrier proteins N6 and N10 conjugated
to HIB capsular polysaccharide. It will be appreciated that
modification of detail may be made without departing from the scope
of the invention. All publications, patents, and patent
applications cited herein are incorporated in full by
reference.
BRIEF DESCRIPTION OF THE FIGURES
[0116] FIG. 1 is a schematic representation of the construction of
the N6 protein.
[0117] FIG. 2 illustrates the N6 and N10 constructs and their
respective DNA and amino acid sequences. The histidine tag, the
flag peptide, the Fxa cutting site and the CD4+ T cell epitopes are
underlined.
[0118] FIG. 3 is a Coomassie-stained SDS-PAGE gel of total protein
extracts prepared from induced E. coli clones producing the
different polyepitope proteins. Lane A: negative control (TG1 cells
containing pQE30 vector with no insert); lane B: TG1 cells
containing the pQE30-N10 plasmid; lane C: TOP10 cells containing
the pTrc-N10 plasmid; lane D: TOP10 cells containing the pTrc-N6
plasmid; lane E: low molecular weight markers.
[0119] FIG. 4 is an immunoblot of the SDS-PAGE gel that is
illustrated in FIG. 3. The Western blot was incubated with a rabbit
antiserum specific for the flag peptide and then with a peroxidated
anti-rabbit IgG antibody. The immune reaction was then revealed
using 4-chloro-1-napthol as substrate for the peroxidase.
[0120] FIG. 5 is an SDS-PAGE Coomassie-stained gel containing
different samples obtained during the procedure of purification of
the N6 protein. Lane A: starting material (total protein of the
induced TOP10 E. coli cells containing pTrc-N6 plasmid; lane B:
soluble proteins (supernatant obtained after centrifugation of the
total protein sample); lane C: proteins soluble in 1M urea
(supernatant obtained after washing the insoluble proteins with 1M
urea); lane D: inclusion bodies (pellet obtained after washing the
insoluble proteins with 1M urea); lane E: N6 protein obtained from
purification on Ni.sup.2+ NTA resin using the immobilised metal
affinity chromatography (IMAC) technique; lane F: low molecular
weight markers.
[0121] FIG. 6 is an immunoblot of the SDS-PAGE gel that is
illustrated in FIG. 5. The Western blot was incubated with a rabbit
antiserum specific for the flag peptide and then with a peroxidated
anti-rabbit IgG antibody. The immune reaction was then revealed
using 4-chloro-1-napthol as substrate for the peroxidase.
[0122] FIG. 7 is a schematic representation of N11 construct and
its respective DNA and protein sequence. The hexahistidine tag, the
flag peptide, the FXa cutting site, and the CD4+ T cell epitopes
are underlined.
[0123] FIG. 8 is a schematic representation of N19 construct and
its respective DNA and protein sequence. The hexahistidine tag, the
flag peptide, the FXa cutting site, and the CD4+ T cell epitopes
are underlined.
[0124] FIG. 9 is an SDS-Page and Coomassie staining of proteins
coming from Top10-Trc-N11 E. coli clone.
[0125] Lane A: Total extract of an uninduced culture.
[0126] Lane B: Total extract of a culture induced using IPTG.
[0127] Lane C: purified N11 protein (solubilisation of whole cells
with guanidinium and IMAC chromatography).
[0128] FIG. 10:
[0129] A: SDS-Page and Coomassie staining. Analysis of the
fractions obtained from IMAC chromatography performed to purify N19
protein. Lane a: prestained molecular weight markers. Lane b: flow
through. Lanes from c to m: gradient fractions showing the purified
N19 protein; the bands having a molecular weight lower than N19 and
visible in the overloaded lanes f, g, and h represents degradation
products of the N19 protein.
[0130] B: SDS-Page and Coomassie staining. Analysis of the
fractions obtained from IMAC chromatography of the N19 conjugated
to Hib polysaccharide. All N19 protein resulted to be conjugated,
as judged by the high molecular weight of the conjugate and by the
absence of 43.0001 kDa unconjugated N19 protein.
[0131] C: The same conjugate samples used in picture B were
subjected to western immuno-blot using an anti-flag antibody. Also
here it can be appreciated that all N19 protein migrated as a very
high molecular weight after conjugation to Hib polysaccharide, and
that there is not unconjugated N19 protein migrating at 43.000
kDa.
[0132] FIG. 11: Proliferative response of two human T cell clones
specific for P30TT (GG-22 clone) and P2TT (KSIMK-140 clone) after
stimulation with the respective synthetic peptides (controls) and
with conjugated or nunconjugated polyepitope proteins (cpm: counts
per minute).
[0133] FIG. 12: Peripheral blood mononuclear cells (PBMC)
proliferation assay. PBMC from three healthy donors, RR, EB and MC,
immune to tetanus toxoid were stimulated with tetanus toxoid, P2TT,
N6, N6-Hib and N10-Hib.
[0134] FIG. 13: Results of the immunogenicity tests performed to
compare the carrier effect of N10, N19, and CRM-197, and to check
for carrier induced immunosuppression phenomena. Anti-Hib titres
obtained after immunising primed and unprimed CD1 mice with
different conjugates.
DETAILED DESCRIPTION OF THE INVENTION
Materials and Methods
[0135] Summary of standard procedures and techniques
[0136] The practice of the present invention will employ, unless
otherwise indicated, conventional techniques of molecular biology,
microbiology, recombinant DNA, and immunology, which are within the
skill of the art. Such techniques are explained fully in the
literature eg. Sambrook Molecular Cloning; A Laboratory Manual,
Second Edition (1989); DNA Cloning, Volumes I and ii (D. N Glover
ed. 1985); Oligonucleotide Synthesis (M. J. Gait ed, 1984); Nucleic
Acid Hybridization (B. D. Hames & S. J. Higgins eds. 1984);
Transcription and Translation (B. D. Hames & Si. Higgins eds.
1984); Animal Cell Culture (R. I. Freshney ed. 1986); Immobilised
Cells and Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide
to Molecular Cloning (1984); the Methods in Enzymology series
(Academic Press, Inc.), especially volumes 154 & 155; Gene
Transfer Vectors for Mammalian Cells (J. H. Miller and M. P. Calos
eds. 1987, Cold Spring Harbor Laboratory); Mayer and Walker, eds.
(1987), Immunochemical Methods in Cell and Molecular Biology
(Academic Press, London); Scopes, (1987) Protein Purification:
Principles and Practice, Second Edition (Springer-Verlag, N.Y.),
and Handbook of Experimental Immunology, Volumes I-IV (D. M. Weir
and C. C. Blackwell eds 1986).
Plasmids, Strains and T Cell Clones.
[0137] PEMBLex2 plasmid was derived from pEMBL8M (Dente L. and
Cortese R., Meth. Enzymol. (1987), 155: 111-9) by inserting a
.lamda.P.sub.L promoter and a polylinker into the EcoRI and HindIII
sites. The commercial vectors pTrc-His and pQE30 were purchased
from Invitrogen and Qiagen respectively. E. coli strains used as
recipients of the above plasmids were: K12.DELTA.H1.DELTA.Trp for
pEMBLex2, TOP10 for pTrc-His and TG1 for pQE30.
[0138] Human T cell clones KSMIK 140 and GG-22 specific for P2TT
and P30TT respectively were kindly provided by Dr. A. Lanzavecchia
(Basel, Switzerland).
Construction of Recombinant Plasmids that Express the N6
Polyepitope Carrier Protein.
[0139] Complementary oligodeoxyribonucleotide pairs coding for
P2TT, P21 TT, P23TT, P30TT1, P32TT and PfT3 T cell epitopes (Table
1) and for a Flag peptide were synthesised using the DNA
synthesiser ABI394 (Perkin Elmer) and the reagents from Cruachem
(Glasgow, Scotland). The oligo pairs were separately annealed in T4
DNA ligase buffer (Boehringer Mannheim) and equimolar amounts of
each annealing reaction were mixed and ligated at room temperature
for 3 hours using T4 DNA ligase (Boehringer Manheim).
[0140] The ligase reaction was then loaded onto a 1% agarose gel
and subjected to electrophoresis. The bands corresponding to the
DNA fragments of expected size were isolated, purified and cloned
into the pEMBLex2 expression vector using standard protocols
(Sambrook et al., 1989). After transformation, a rabbit antiserum
specific for the Flag peptide was used to perform colony-screenings
(Sambrook et al., 1989) in order to identify recombinant protein
producing clones. Protein extracts from positive clones were
analysed using SDS-PAGE to further select for clones on the basis
of recombinant protein size.
TABLE-US-00001 TABLE I CD4+ T cell epitopes inserted in the
recombinant polyepitope carrier proteins. T cell Aminoacid epitope
position Aminoacid sequence References P23TT 1084-1099
VSIDKFRIFCKANPK Demotz et al. 1993 Eur. J Immunol 23: 425 P32TT
1174-1189 LKFIIKRYTPNNEID Demotz et al. 1993 Eur. J Immunol S 23:
425 P21TT 1064-1079 IREDNNITLKLDRCN Dr. Lanzavecchia, pers. comrn.
N PF T3 380-398 EKKIAKMEKASSVF Hammer et al. 1993 Cell 74: I97 NVVN
P30TT 947-967 FNNFTVSFWLRVPK Demotz et al. 1993 Eur. J Immunol
VSASHLE 23: 425 P2TT 830-843 QYIKANSKFIGITE Demotz et al. 1993 Eur.
J Immunol 23: 425 HA 307-319 PKYVKQNTLKLAT Alexander et al. 1994
Immunity 1: 751 HBVnc 50-69 PHHTALRQAILCWG Alexander et al. 1994
Immunity 1: ELMTLA 751 HBsAg 19-33 FFLLTRILTIPQSLD Greenstein et
al. 192 J Immunol 148: 3970 MT 17-31 YSGPLKAEIAQRLE Alexander et
al. 1994 Immunity 1: DV 751 HSP70 408-427 QPSVQIQVYQGER Adams et
al. 1997 Infect Immun EIASHNK 65: 1061 Flag MDYKDDDD peptide
[0141] After nucleotide sequencing of the selected clones, a clone
named pEMBLN6 was shown to contain six different T cell epitopes
with no repetitive sequences. The N6 insert was then PCR-amplified
and transferred to pTrc-His expression vector (Invitrogen) using
standard techniques (Sambrook et al., 1989). The generation of the
N6 expressing plasmids is summarised in FIG. 1.
Construction of Recombinant Plasmids that Express the N10
Polyepitope Carrier Protein
[0142] Using synthetic oligodeoxyribonucleotides and standard
cloning techniques (Sambrook et al., 1989), four additional CD4+ T
cell epitopes were added to the N6 protein: HBVnc, HA, HbsAg, and
MT (Table I). HBVnc and HA were sequentially introduced into
pTrc-N6 by means of two consecutive cloning steps; to the resulting
plasmid the HbsAg and MT epitopes were added in a single cloning
step.
[0143] After DNA sequencing, a correct construct (pTrc-N10) coding
for the expected ten epitope polyepitope protein was identified.
The N10 coding insert was then transferred from pTrc-N10 to pQE30
(Qiagen) by means of PCR. The sequence of the resulting pQE-N10
construct was then confirmed by DNA sequencing.
Construction of the Recombinant Plasmid Expressing N11 Polyepitope
Carrier Protein.
[0144] Two complementary oligodeoxyribonucleotides were synthesised
and annealed to obtain a DNA linker coding for the HSP70 CD4+ T
cell epitope (Table I). The linker was inserted in pTrc-N10 plasmid
downstream from N10 coding region and in frame with it. After
transformation in TOP10 E. coli strain, the transformants were
selected using protein expression and DNA sequencing analyses.
Glycerol batches of a selected clone (TOP10/pTrc-N11) having the
correct coding sequence and expressing a protein of the expected
molecular weight were stored to -80.degree. C.
Construction of Recombinant Plasmids that Express the N19
Polyepitope Carrier Protein.
[0145] The DNA fragment encompassing the coding region from P23TT
to HBsAg was PCR amplified using the plasmid pTrc-N10 as template
and two oligonucleotide primers which allow the insertion of BgIII
and PstI restriction sites respectively at the 5' and 3' ends of
the PCR product. The plasmid pTrc-N10 was digested with BamHI and
PstI restriction enzymes and ligated to the PCR product digested
with BgIII and PstI. After transformation in TOP 10 cells and
selection of the transformants using protein expression and DNA
sequencing analyses, glycerol batches of a selected clone
(TOP10/pTrc-N19) having the correct coding sequence and expressing
a protein of the expected molecular weight were stored to
-80.degree. C.
[0146] The pTrc-N19 plasmid was digested with EcoRV and PstI and
the insert was cloned in pQE-N10 digested with the same enzymes.
After transformation in TG1 cells and selection of the
transformants using protein expression and DNA sequencing analyses,
glycerol batches of a selected clone (TG1/pQE-N19) having the
correct coding sequence and expressing a protein of the expected
molecular weight were stored to -80.degree. C.
Purification of the Polyepitope Carrier Proteins.
[0147] All the recombinant polyepitope carrier proteins were
purified using a similar strategy. Briefly, E. coli cultures were
grown in 500 ml LB medium containing 100 .mu.g/ml Ampicillin, at
37.degree. C. At 0.3-0.5 OD.sub.600, the expression of the
polyepitope proteins was induced for 3-5 hours by adding 0.1-1 mM
IPTG. Cells were disrupted by sonication or French press, the
insoluble fraction was collected by centrifiagation, dissolved with
buffer A (6 M guanidiniwn-HCL, 100 mM NaH.sub.2PO.sub.4, 10 mM Tris
base, pH 8) and adsorbed with 2 ml of Ni.sup.2+NTA resin
(Qiagen).
[0148] Then, the resin was packed in a column and washed with
buffer A. Guanidinium-HCl was removed from the column by washing
with buffer B (8 M Urea, 100 mM NaH.sub.2PO.sub.4, 10 mM Tris base)
pH 8. After a wash with buffer B pH 6.5, recombinant proteins were
eluted with a 20 ml buffer B gradient from ph 6.5 to pH 4. The
factions containing the purified recombinant proteins were pooled
and dialysed against PBS, pH 7.2. Proteins were analysed by
SDS_PAGE and protein content was determined using the Bradford
method. Alternatively, cell pellets obtained from E. coli cultures
were solubilized by heating at 37.degree. C. in buffer A, the
lysates were centrifuged to 15.000 g for 20 min. The supernatants
were subjected to column chromatography on Nickel activated
Chelating Sepharose Fast Flow (Pharmacia). After a wash with buffer
A and a wash with buffer B, pH 7, the proteins were separated by
collecting fractions from a 0-200 mM gradient of Imidazole in
buffer B, pH 7. The fractions containing the purified recombinant
proteins (as judged by SDS-PAGE and Coomassie staining) were pooled
and dialysed against PBS, pH 7.2.
Preparation and Activation of Hib Oligosaccharides.
[0149] The Hib capsular polysaccharide can be prepared according to
the protocol described in Gotschlich et al. (1981) J. Biol. Chem.
256: 8915-8921.
[0150] 1.99 L of a 10 mg/ml solution of Hib polysaccharide was
hydrolysed in 0.01M acetic acid at 76.degree. C. for 5 hours. After
chilling, neutralization and 0.2 .mu.m filtration, the resulting
oligosaccharide population had an average degree of polymerisation
(avDP) of 8 as measured by the chemical ratio between ribose and
reducing groups.
[0151] NaCl was then added to the hydrolysate until a concentration
of 0.16 M was attained, then diluted 1:1 with 0.16M NaCl/10 mM
acetate pH 6 and submitted to tangential flow ultrafiltration on a
10 kDa membrane in order to remove high molecular weight
species.
[0152] Ultrafiltration comprised approximately 11-fold
concentration followed by 15 cycles of diafiltration against 0.16 M
NaCl/10 mM acetate, pH 6. The retentate was discarded. The permeate
was diluted:1 with water and 0.22 .mu.m filtered. Chemical analysis
revealed an avDp of 8.1.
[0153] The permeate obtained from 10 kDa UF was loaded, at a linear
flow rate of 150 cm/h, onto a Q-Sepharose Fast Flow column [10 cm
(ID); 5.5 cm (h)] equilibrated with 0.08 M NaCl/0.05 M sodium
acetate pH 6. After adsorption, low molecular weight fragments (up
to 5 repeats) were removed by washing the column with 10 column
volumes of equilibrating buffer and then eluted with 3 column
volumes of 0.5 M NaCl/0.005M sodium acetate pH 6. The eluate was
0.2 .mu.m filtered and then analysed for avDp and ion exchange
analytical chromatography. AvDP resulted at 17.3, ion exchange
analytical chromatography on Mono Q HR 5/5 revealed the absence of
any small fragments until DP 5.
[0154] To introduce a terminal amino group, reductive amination was
then performed; to the fractionated Hib oligosaccharide obtained
from Q-Sepharose chromatography, ammonium chloride 35 mg/ml and
sodium cyanoboroidride 12 mg/ml final concentrations were added.
After stirring, the solution was 0.2 .mu.m filtered and incubated
at 37.degree. C. for 120 hours. The amino oligosaccharide was then
purified from excess of reagents by precipitation with 95.degree.
EtOH (81.degree. final concentration) in the cold for 15-20 hours.
The precipitated oligosaccharide was then recovered by
centrifugation, solubilized in NaCl 0.4M using approximately 1/4 of
the starting volume and precipitated again at 81.degree. EtOH in
the cold for 15-20 hours.
[0155] The amino-oligosaccharide was again recovered by
centrifugation and solubilized in about 300 ml of 0.02 M NaCl.
After having taken a sample for analysis, the resulting solution
was then dried using a rotary evaporator.
[0156] Colorimetric amino group analysis confirmed the introduction
of a primary amino group into the oligosaccharide.
[0157] Derivatisation to active ester was then performed as
follows. The amino-oligosaccharide was solubilised in distilled
water at a concentration of 40 .mu.mol of amino groups per ml. The
solution was then diluted 10-fold with DMSO. Triethylamine was
added in molar ratio to the amino groups of 2:1.
N-hydroxysuccinimido diester of adipic acid was then added in a
molar ratio to the amino groups of 12:1. The reaction mixture was
kept under gentle stirring for 2 hours at RT. The activated
oligosaccharide was then purified from the excess of reagents by
precipitation into 10 volumes of 1-4 dioxane under stirring. After
30 minutes in the cold the precipitate was collected onto a
syntered glass filter, washed onto the filter with dioxane and then
dried under vacuum. The dried activated oligosaccharide was
analysed for its content of active ester groups by a colorimetric
method; this test showed the presence of 62.1 .mu.mol of active
ester per mg of dried oligosaccharide.
[0158] The above-obtained activated oligosaccharide was then used
for conjugation experiments.
Conjugation of the Polyepitope Carrier Protein with Hib Capsular
Oligosaccharides and Purification of the Conjugates.
[0159] 33.4 nmoles of recombinant carrier protein and 669 nmoles of
activated Hib oligosaccharide in a final volume of 0.5 ml 10 mM
phosphate buffer, pH 7, were gently stirred overnight at RT and
brought up to 5 ml 1M (NH.sub.4).sub.2SO.sub.4, 10 mM phosphate
pH7. The sample was subjected to FPLC on a 1 ml Phenyl Sepharose
5/5 HR column (Pharmacia). 1 ml fractions were collected both
during washing (1M (NH.sub.4).sub.2SO.sub.4, 10 mM phosphate, pH 7)
and elution (10 mM phosphate, pH 7). Two peaks corresponding to the
non-adsorbed material and to the eluted material were obtained. The
pooled fractions corresponding to the non-adsorbed material and the
pooled fractions corresponding to the elution peak were subjected
to protein and ribose content determination and to SDS-PAGE and
Western blot analysis.
[0160] A protocol to conjugate recombinant proteins to
oligosaccharides directly on Ni.sup.2+-NTA resin was also
developed. Recombinant proteins were purified as described above,
but the final dialysis step was omitted. The protein content of the
8M urea fraction pool was measured with the Bradford assay. The pH
of the eluted proteins was adjusted to pH8 and adsorption on 1 ml
pre-equilibrated Ni.sup.2+-NTA resin was again performed in a batch
mode. Urea was removed by washing with 4.times.25 ml 100 mM
phosphate buffer pH 7.5. The resin was suspended in 1 ml 100 mM
phosphate buffer pH 7.5 and a 20-fold molar excess of activated Hib
oligosaccharide (as compared to the protein that was adsorbed on
the resin) was added to the suspension. The mixture was gently
stirred overnight at RT packed in a column, and washed with 50 ml
100 mM phosphate buffer pH 7.5 to remove unconjugated
oligosaccharide.
[0161] Elution of the conjugate was performed with 100 mM phosphate
buffer pH 4. Peak fractions were pooled and dialysed against PBS,
pH 7.2. The conjugate was analysed by Coomassie staining of
SDS-PAGE gels and Western immunoblot using an anti-flag rabbit
antibody. The protein/carbohydrate ratio of the glycoconjugate was
determined upon Bradford assay and ribose content
determination.
Cultures of PBMCs and T Cell Clones.
[0162] Culture medium for PBMCs was RPMI 1640 (Gibco Laboratories,
Paisley, Scotland) supplemented with 2 mM L-glutamine, 1%
nonessential amino acids, 1 mM sodium pyruvate, gentamycin (50
.mu.g/ml), and 5% human serum (RPMI-HS) or 10% foetal calf serum
(RPMI-FCS). For the growth of T-cell lines and clones, RPMI-HS was
supplemented with 50 U of recombinant interleukin-2 (rIL-2:
Hoffmann La Roche, Nutley, N.J.) per ml.
PBMC Proliferation Assay.
[0163] Frozen PBMC (10.sup.5) from healthy adults immune to tetanus
toxoid were thawed and cultured in duplicate wells of 96-well
flat-bottomed microplates, in 0.2 ml of RPMI-HS (Di Tommaso et al,
1997). The recombinant proteins and tetanus toxoids (Chiron, Siena)
were added to wells at the final concentration of 10 .mu.g/ml.
After 5 days of culture. 1 .mu.Ci of [.sup.3H] thymidine (specific
activity: 5 Ci/mmol, Amersham) was added to each well and
DNA-incorporated radioactivity was measured after an additional 16
hrs by liquid scintillation counting.
Proliferation Assay of T Cell Clones.
[0164] Two Human T cell clones, KSMIK 140, and GG-22, specific for
P2TT and P30TT respectively, and the respective peptides were
kindly provided by Dr. A. Lanzavecchia (Basel, Switzerland). T
cells (2.times.10.sup.4) were cultured with autologous irradiated
Epstein Barr Virus-transformed B lymphocytes (3.times.10.sup.4) in
0.2 ml of RPMI-FCS in 96-well flat-bottomed microplates in
duplicate wells. Synthetic peptides and conjugated or unconjugated
recombinant proteins were added to cultures at a final
concentration of 10 .mu.g/ml. After 2 days, 1 .mu.Ci of
[.sup.3H]thymidine was added and the radioactivity incorporated was
measured by liquid scintillation counting after an additional 16
hours.
[0165] In some experiments, carrier proteins and their conjugates
were pre-incubated with APCs for 2-4 hours, then APCs were washed
and cultured with T cell clones. This procedure was used to limit
possible proteolytic degradation by serum proteases and to be more
confident that epitope presentation would be due to
intracellularly-processed epitopes.
Immunogenicity Tests.
[0166] In a first experiment, equal doses of the glycoconjugates
and of the polysaccharide (2.5 .mu.g as polysaccharide) in presence
of 0.5 mg of aluminium hydroxide as adjuvant were injected
subcutaneously into groups of eight BALB/c and C57BL/6 mice
(female, 7-week-old) on days 0, 21 and 35. Mice were bled on day -1
(pre-immune), 20 (pre-2), 34 (pre-3) and 45 (post-3) and individual
sera collected and stored at -80.degree. C. before ELISA assay.
[0167] In a second experiment, equal doses of the glycoconjugates
and of the polysaccharide (2.5 .mu.g as polysaccharide) in the
presence of 0.5 mg of aluminium hydroxide as adjuvant were injected
subcutaneously into groups of eight Swiss ('D1 and BALB/c mice
(female, 7-week-old) on days 0, 10 and 20. A boost of 2.5 .mu.g of
purified Hib polysaccharide (HibCPS) in presence of 0.5 mg of
aluminium hydroxide was then given to each mouse at day 70. Mice
were bled on day -1 (pre-immune). 35 (post-vaccination), 68
(pre-boost) and 85 (post-boost) and individual sera collected and
stored at -80.degree. C. before ELISA assay.
[0168] In a third experiment, equal doses of CRM-Hib, N10-Hib, and
N19-Hib (2.5 .mu.g as polysaccharide) in presence of 0.5 mg of
aluminium hydroxide as adjuvant were injected subcutaneously in
groups of 6 Swiss CD1 mice (female, 7-week-old) on days 0, 15, and
28 in order to compare the carrier effects. Different groups of
mice were also subjected to the same schedule but were previously
primed with unconjugated carriers in order to check for potential
immunosuppression phenomena. In the latter groups equal doses of
carrier proteins (50 .mu.g) in 0.5 mg alum were injected on day
-30. All mice were bled on day -32 (pre-priming), -2 (pre-immune),
14 (post-1), 27 (post-2), and 45 (post-3) and the sera were
collected and stored to -80.degree. C. before ELISA assay.
ELISA.
[0169] Nunc Maxisorp 96-well flat-bottomed plates were coated by
overnight incubation at 4.degree. C. with 1 .mu.g/ml (as
polysaccharide) of a human serum albumin (HSA) and H. influenzae
type b polysaccharide conjugate (HSA-Hib). After washing, wells
were over-coated using 1% (w/v) gelatin in PBS, pH 7.2 for 3
additional hours at 37.degree. C. Serum samples were diluted 1:50
in 5 mM phosphate buffer, pH 7.2 containing 75 mM NaCL 1% (w/v) BSA
and 0.05% (w/v) Tween-20 and dispensed in duplicate into the wells.
Sera from untreated mice were pooled and diluted 1:50 as above and
dispensed into 8 wells. After overnight incubation at 4.degree. C.,
plates were washed three times with 5 mM phosphate buffer, pH 7.2
containing 75 mM NaCl and 0.05% (w/v) Tween-20. Then, alkaline
phosphate-conjugated goat IgG anti-mouse IgG diluted 1:1000 and 5
mM phosphate buffer, pH 7.2 containing 75 mM NaCl. 1% (w/v) BSA and
0.05%. (w/v) Tween-20 were added to each well, and incubated 3
hours at 37.degree. C.
[0170] After repeated washing, 100 .mu.l of a chromogen-substrate,
p-nitrophenylphosphate, in a diethylenamine solution, were added to
each well. Reaction was stopped after 20 min by adding a 4N NaOH
solution. Then, the plate was read at 405 mM with a reference
wavelength of 595 mM. Titres were expressed as absorbencies at 405
mM (A.sub.405mm). Mice were considered responders when the average
A.sub.405mm was found equal to or higher than four times the
average of absorbencies of the eight wells with the sera from
untreated animals. According to the European Pharmacopoeia
[PA/PH/Exp15/T(93)3ANP] four out of eight mice should be
responders.
[0171] In the second experiment, mice were considered responders
when the average A.sub.405mm was found four times the average of
the absorbencies of eight pre-immune sera of the same group of
treatment.
[0172] The anti-carrier response was assayed as above described for
anti-Hib response using plates coated with N10 or N6 (coating
concentration=2 .mu.g/ml).
Results
Construction of the Polyepitope Carrier Proteins.
[0173] Using the approaches described in materials and methods, we
created several E. coli clones expressing different carrier
proteins. The following table lists only the six clones we utilised
to purify the recombinant polyepitope carrier proteins:
TABLE-US-00002 Expressed Theoretic E. coli Ex- Name of polyepitope
Number of Mol. W. host pression the clone protein aminoacids (kDa)
strain vector Top10- N6 143 16 Top10 pTrc-His Trc-N6 Top10- N10 218
24 Top10 pTrc-His Trc-N10 TG1-QE- N10 218 24 TG1 pQE30 N10 Top10-
N11 240 27 Top10 pTrc-His Trc-N11 Top10- N19 390 43 Top10 pTrc-His
Trc-N19 TG1-QE- N19 390 43 TG1 pQE30 N19
[0174] The clone expressing N6 protein comprised the plasmid
pTrc-N6 transformed in the Top10 E. coli strain. As deduced from
plasmid DNA sequencing, this plasmid code for a protein having an
hexahistidine amino terminal tail followed in sequence by a flag
peptide, a FXa site, and the following T cell epitopes: P23TT,
P32TT, P21TT, PfT3, P30TT, and P2TT. All the epitopes were spaced
by a KG aminoacid sequence (FIG. 2).
[0175] The two clones that produced N10 protein were the Top10 E.
coli strain containing the plasmid pTrc-N10, and the TG1 E. coli
strain containing the plasmid pQE-N10. Both these clones contained
the N6 coding sequence fused to a carboxy terminal sequence coding
for four additional T cell epitopes which were in the order: HBVnc,
HA, HBsAg, and MT (FIG. 2).
[0176] The clone that produced N11 protein comprised the plasmid
pTrc-N10 transformed in the Top10 E. coli strain. As deduced from
plasmid DNA sequencing, this plasmid code for a protein consisting
in the N10 sequence fused to a carboxy terminal sequence coding for
the HSP70 T cell epitope (FIG. 7).
[0177] The two clones that produced N19 protein were the Top10 E.
coli strain containing the plasmid pTrc-N19, and the TG1 E. coli
strain containing the plasmid pQE-N19. Both these clones contained
the N10 coding sequence fused to a carboxy terminal sequence coding
for nine additional T cell epitopes which were in the order: P23TT,
P32TT, P21TT, PfT3, P30TT, P2TT, HBVnc, HA, and HBsAg (FIG. 8).
Protein Expression and Purification.
[0178] FIGS. 3 and 4 depict protein expression of the three
synthetic proteins. The addition of four new epitopes (HBVnc, HA,
HbsAg, and MT) to N6 in pTrc-His (lane D) to obtain N10 protein
(lane C) resulted in a remarkable reduction of protein expression.
An attempt to increase the expression level of N10 simply involved
changing the expression vector (from pTrc)-His to pQE30) and the E.
coli strain (from Top10 to TG1). As seen in FIGS. 3 and 4, the
amount of N10 expressed by pQE30-N10 in TG1 (lane B) was notably
higher than the same protein expressed by pTrc-N10 (lane C). This
is thought possibly to be due to the fact that whereas N6 protein
was effectively assembled by the E. coli strain in the order of
epitopes most suited to the organism, whereas the addition of four
further epitopes was effectively forced and thus was less natural.
However, the fact that the level of N10 expression was notably
increased by simply changing expression vector (from pTrc-His to
PQE30) and E. colit strain (from TOP-10 to TG1) suggests that
additional factors, other than epitope combination, play a role in
protein expression.
[0179] FIG. 9 shows protein expression and purification of the N11
protein (SDS-PAGE and Coomassie staining). Total extract coming
from an induced culture (lane B) shows an induced band,
corresponding roughly to the expected molecular weight of N11
protein, that is not present in uninduced extract (lane A). The
identity of the induced band was established also by western blot
using an anti-flag antibody, and was also deduced from plasmid DNA
sequencing (FIG. 7). N11 purification (FIG. 9, lane C) was done by
solubilising whole cell pellets in guanidinium and by subjecting
the whole extract to IMAC chromatography, with this procedure we
obtained 14 mg of recombinant N11 protein from one litre of
Top10-Trc-N11 flask culture. The addition of HSP70 T cell epitope
to the carboxy terminus of N10 resulted in a construct (pTrc-N11)
that was able to notably improve the expression of the polyepitope
protein as compared to the expression obtained from pTrc-N10.
[0180] As it was for the N10 protein, also the expression of N19
protein was improved by changing the expression vector (from
pTrc-His to pQE30) and the host strain (from Top10 to TG1).
TG1(QE-N19) was used to purify N19 polyepitope protein. By
subjecting solubilised inclusion bodies to IMAC chromatography, we
purified (see FIG. 10A) 5.42 mg of N19 protein from one litre of
flask culture. The identity of N19 was identified in SDS-Page as an
induced band having the expected molecular weight, in immuno
western blot using an anti-flag antibody, and was also deduced
after plasmid DNA sequencing (FIG. 8).
[0181] All clones expressing recombinant polyepitope proteins
produced them mainly in the form of inclusion bodies. Purification
of N6 and N10 proteins from inclusion bodies solubilised with 8M
urea using an immobilised metal affinity chromatography (IMAC)
procedure in the presence of 8M urea resulted in the loss of a high
percentage of protein which was elutable with a 6.5-4 pH gradient
(data not shown).
[0182] On the contrary, almost all of the histidine-tagged protein
was eluted with the 6.5-4 pH gradient when starting inclusion
bodies were solubilised with 6M guanidine hydrochloride (FIGS. 5
and 6). Using this protocol 7.8 mg of N6 was purified from a litre
of culture. The N10 protein that was employed in immunisation and T
cell proliferation experiments was purified from pTrc-N10
clone.
[0183] Given the lower expression of recombinant protein shown by
this clone we decided to purify N10 protein by solubilising whole
cells with guanidinium in such a way as to exploit soluble and
insoluble (inclusion bodies) proteins for IMAC purification. With
this procedure 1.5 mg of purified N10 protein was obtained from a
litre of culture. The higher success of solubilisation using 6M
guanidium is thought to be due to the ability of this compound to
solubilise the carrier proteins in monomeric form.
Hib Oligosaccharide Conjugation to Polyepitope Proteins.
[0184] Using the phenyl sepharose FPLC protocol we obtained a
purified N6-Hib conjugate having a protein content of 79.4
.mu.g/ml; and an oligosaccharide content of 42.7 .mu.g/ml.
[0185] We observed that 30% of conjugated protein was unable to
bind to phenyl sepharose in the presence of 1M
(NH.sub.4).sub.2SO.sub.4. In addition, 30-40% of carrier protein
was previously lost during a dialysis step to remove urea before
the conjugation reaction. To overcome these problems it was checked
if it was possible to perform the conjugation reactions when the
protein was adsorbed on the Ni.sup.2+-NTA resin. We observed that
the Hib oligosaccharide was unable to bind Ni.sup.2+-NTA resin at
any pH, suggesting the feasibility of this approach and predicting
that no interference due to the oligosaccharide could influence the
elution of the protein once conjugation had taken place.
[0186] A reaction was thus set up involving protein adsorption on
Ni.sup.2+-NTA resin in the presence of 8M urea, urea removal,
conjugation with oligosaccharide, washing, and conjugate elution.
No aggregation phenomena were observed for the eluted conjugate.
Using this procedure we obtained a purified N6-Hib conjugate having
a protein content of 320 .mu.g/ml and an oligosaccharide content of
370 .mu.g/ml. and a purified N10-Hib having a protein content of
113 .mu.g/ml and an oligosaccharide content of 114 .mu.g/ml.
[0187] By using a 1:10 protein to carbohydrate molar ratio to
conjugate oligosaccharide to recombinant carriers, we observed that
a fraction of protein remained unconjugated (as judged by Coomassie
staining of SDS-PAGE gel and Western immunoblot; data not shown).
When a 1:20 protein to carbohydrate stoichiometric ratio was used,
all the purified recombinant proteins were found to be completely
conjugated, in fact, by analysing Coomassie-stained gels and
western immunoblots using an anti-Flag antibody. We observed that
after conjugation of N6 and N10 with Hib oligosaccharides these
molecules increased their molecular weight, appearing as a high
molecular weight smear, and proteins were no longer visible at the
expected molecular weight for N6 and N10 monomers. This suggested
that the synthetic proteins were completely conjugated to Hib
oligosaccharides (data not shown).
[0188] The conjugation of activated Hib oligosaccharide to N19
protein resulted in a protein content of 173 .mu.g/ml and in an
oligosaccharide content of 127 .mu.g/ml. FIG. 10B depicts an
SDS-Page and Coomassie staining analysis of the fractions obtained
from IMAC chromatography of the N19 conjugated to Hib
polysaccharide. All N19 protein resulted to be conjugated, as
judged by the high molecular weight of the conjugate and by the
absence of 43.000 kDa unconjugated N19 protein. FIG. 10C shows the
corresponding western immuno-blot using an anti-flag antibody. Also
here it can be appreciated that all N19 protein migrated as a very
high molecular weight after conjugation to Hib polysaccharide, and
that there is not unconjugated N19 protein migrating at 43.000
kDa.
Recognition of Carrier Proteins and their Conjugates by Human T
Lymphocytes.
[0189] To investigate whether T cell epitopes contained in the
polypeptides were recognised by human T cells we used T cell clones
specific for the IT universal epitopes p2TT and p30TT (Demotz et
al. 1993). FIG. 11 shows that N6 is recognised by both clones not
only as a simple polypeptide but also after it has been conjugated
with polysaccharide. Remarkably, N6-Hib is recognised even better
than unconjugated N6 by the T cell clone specific for P2TT. N10-Hib
is recognised by the clone specific for p2TT but is poorly
recognised by the clone specific for P30TT. In both cases N10-Hib
exerts the same stimulatory activity as the synthetic peptide. The
N10 clone was not tested in these experiments.
[0190] Once assessed that the T cell epitopes contained in the
carrier proteins are correctly presented to T lymphocytes, we asked
whether these carriers maintain their stimulatory capacity when
presented to a heterogeneous population of lymphocytes such as
PBMC. This could be predictive of whether our carriers might
function as such once injected into subjects immune to antigens
whose epitopes are included in the carriers themselves. For this
purpose we used PBMC from donors immune to TT (A. Di Tommaso et al.
1997), since TT epitopes are the most represented in our
polypeptides. FIG. 12 shows that all the formulations were able to
stimulate PBMC proliferation.
[0191] However, the incubation of PBMC with a synthetic peptide
representing one of the epitopes included in both N6 and N10
constructs failed to exert a stimulatory effect. As a positive
control, the PBMC were also incubated with 10 .mu.g/ml of TT, that
in all cases induced a proliferative response. Interestingly, the
N6 polyepitope protein turned out to be the most potent PBMC
stimulator among those tested in two out of three volunteers.
Immunogenicity Tests.
[0192] The carrier effect of the proteins N10 and N6 in comparison
with CRM197 was assayed in mice in several glycoconjugate vaccines.
Once coupled to Hib oligosaccharides the carrier proteins were
injected in different mouse strains to verify the potential of
their carrier effect. In BALB/c mice, an equivalent anti-Hib
response was found when CRM197 and N10 were used as carrier
proteins, whilst a lower response was found when N6 was used as
carrier protein. This result was evident when the results were
expressed using titres, while responder percentages failed to
evidence the lower anti-Hib response obtained with the N6 protein
carrier.
[0193] In C57BL/6 mice, the N6 protein gave a negative result,
while positive results were obtained with CRM197 and N10, even if
to a lower extent. These results were evident both using titres or
responder percentages to express the results. When the results were
expressed as a responder percentage, the high carrier effect of
CRM197 and N10 was well evidenced with respect to N6, whose results
were lower than 50% at day -34 and day -45 bleedings, after a
comparable primary response (pre-2 bleeding, day 20).
[0194] Table II reports the results of the experiments in BALB/c
and C57BL/6 mice.
[0195] In Swiss CDI mice, the titres obtained with the N10 carrier
protein were equivalent to those obtained with CRM197. The anti-Hib
titres increased after immunisation up to the 70th day, when a
polysaccharide boost was given to assay whether or not an
immunological memory was induced in the treated mice. No boost
effect was observed with any carrier, although when CRM197 or N10
were used as carrier protein the titre did not decrease. In this
mouse strain the immunisation with N6-Hib glycoconjugate give
results very similar to the controls (polysaccharide and alum). The
boost effect was not evidenced even in BALB/c mice that evoke a
lower response with respect to Swiss CD1 mice.
[0196] The results are summarised in Table III.
[0197] Immunisation of different mice strains with Hib
oligosaccharides conjugated to the artificial carrier proteins
resulted in a good carrier effect exerted by N10, whilst N6 gave
unsatisfactory results. This suggests that the size of the protein
or the number of T cell epitopes has a high influence in providing
T cell help to the oligosaccharides.
[0198] We used outbred CD1 mice to perform an immunogenicity
experiment in which the carrier effect of N19 protein was compared
to the carrier effects of N10 and CRM197. In addition, in order to
explore potential carrier-induced immunosuppression phenomena, the
three doses of N10-Hib, N19-Hib and CRM-Hib were given to groups of
mice that did not received carrier priming and to groups of mice
that one month before were primed with 50 .mu.g of the respective
unconjugated carrier (see materials and methods).
TABLE-US-00003 TABLE II RESPONDER (%) A.sub.405 .times. 1000
(GMT's) DAY BLEEDING N10-Hib N5 + 146-Hib CRM-Hib N10-Hib N5 +
146-Hib CRM-Hib BALB/c MICE 0 PRE-IMMUNE 0 0 0 10 17 12 20 PRE-2
33.3 33.3 50 135 162 257 34 POST-2/PRE-3 100 100 100 2022 1356 1969
45 POST-3 100 100 100 1717 1368 1616 C57BL/6 MICE 0 PRE-IMMUNE 0 0
0 28 38 31 20 PRE-2 83.3 83.3 83.3 136 192 609 34 POST-2/PRE-3 83.3
33.3 100 1451 306 2612 45 POST-3 100 33.3 100 1731 222 2240
TABLE-US-00004 TABLE III SWISS CD1 MICE TITRE GMT's (A.sub.405 nm
.times. 10.sup.3) DAY BLEEDING CRM-Hib N5 + 146-Hib N10-Hib PsHib
ALUM -1 PRE-IMMUNISATION 59 98 156 166 175 35 POST-IMMUNISATION
1577 471 1007 227 243 68 PRE-BOOST 2082 889 1789 590 461 85
POST-BOOST 2073 630 1767 364 479 SWISS CD1 MICE RESPONDER (%) DAY
BLEEDING CRM-Hib N5 + 146-Hib N10-Hib PsHib ALUM -1
PRE-IMMUNISATION 0 0 0 0 0 35 POST-IMMUNISATION 100 50 62.5 0 0 68
PRE-BOOST 87.5 87.5 100 25 25 85 POST-BOOST 87.5 62.5 85.7 12.5
37.5
[0199] The schedule of the experiment was the following:
TABLE-US-00005 Days Group -32 -30 -2 0 14 15 27 28 45 1 bleeding
DT* bleeding CRM-Hib bleeding CRM-Hib bleeding CRM-Hib bleeding 2
bleeding bleeding CRM-Hib bleeding CRM-Hib bleeding CRM-Hib
bleeding 3 bleeding N10 bleeding N10-Hib bleeding N10-Hib bleeding
N10-Hib bleeding 4 bleeding bleeding N10-Hib bleeding N10-Hib
bleeding N10-Hib bleeding 5 bleeding N19 bleeding N19-Hib bleeding
N19-Hib bleeding N19-Hib bleeding 6 bleeding bleeding N19-Hib
bleeding N19-Hib bleeding N19-Hib bleeding *For priming we used a
chemically detoxified diphtheria toxin (DT: diphtheria toxoid)
instead of the non toxic mutant (CRM-197) of diphtheria toxin.
[0200] The results are depicted in FIG. 13. In unprimed mice the
best anti-Hib titres were obtained using N19-Hib, whilst CRM-Hib
and N10-Hib gave lower titres. According to the known direct
proportion between the size of the carrier molecules and the
exerted carrier effect, N19-Hib elicited a clearly improved
anti-Hib response as compared to N10-Hib. In addition N19-Hib seems
slightly superior also when compared to CRM-Hib suggesting the
feasibility to substitute "classical" carrier proteins with the
recombinant CD4+ polyepitope proteins. In contrast to the previous
immunogenicity test performed on CD1 mice, were the carrier effects
of N10 and CRM-197 were similar, in this new test the mean anti-Hib
titre elicited by N10-Hib was notably lower than the one obtained
with CRM-Hib.
[0201] In primed mice the best results, were obtained with N19-Hib,
which elicited a better response also when compared to the response
obtained in unprimed mice, suggesting a potentiation due to the
priming with N19 protein. A slight potentiation was also obtained
after priming with N10. Conversely, anti-Hib response obtained with
CRM-Mb in primed mice was notably lower of the response obtained in
unprimed mice, confirming the carrier induced immunosuppression
often observed with the carriers in current use.
[0202] Since N10 and N19 contains five and ten tetanus toxoid T
cell epitopes respectively, we subjected N10-Hib and N19-Hib to an
immunogenicity test in CD1 mice primed with tetanus toxoid. The
goal of this experiment was to check whether in primed mice the
anti-Hib titers were improved in comparison to non-primed mice.
Surprisingly, tetanus toxoid priming potentiated the immunoresponse
to Hib in mice immunised with N10-Hib but not in mice that received
N19-Hib (data not shown).
[0203] From the performed immunogenicity tests we can make the
following few conclusions: [0204] 1. The carrier effect of the
polyepitope protein is directly related to its size. [0205] 2.
Recombinant polyepitope proteins N10 and N19 can parallel or exceed
CRM-197 as carriers. [0206] 3. The polyepitope carrier proteins do
not suffer of carrier induced suppression.
REFERENCES
[0206] [0207] Agadjanyan M, Luo P, Westerink M A J, Carey L A,
Jutchins W, Steplewski Z, Weiner D B, Kieber-Emmons T (1997)
Peptide mimicry of carbohydrate epitopes on human immunodeficiency
virus. Nature Biotech. 15: 547-551. [0208] Ahlers J. D., (1993) J.
Immunol. 150: 5647-5665. [0209] Anderson P, Picchichero M E; Insel
R A 91985). Immunogens consisting of oligosaccharides from the
capsule of H. influenzae type b coupled to diphtheria toxoid or the
toxin protein CRM.sub.197 J Clin Invest 76: 52-59. [0210] Anderson
P, Pichichero M E, Insel R A (1985). Immunization of 2-month-old
infants with protein-coupled oligosaccharides derived from the
capsule of H. influenzae type b. J Pediatr 107: 346-351. [0211]
Anderson P. (1983) Antibody responses to H. Influenzae type b and
diphtheria toxin induced by conjugates of oligosaccharides of the
type b capsule with the non-toxic protein CRM19. Infect Immun. 39:
233-238 [0212] Andreoni J, Kaythy H, Densen P (1993) Vaccination
and the role of capsular polysaccharide antibody in prevention of
recurrent meningococcal disease in late complement
component-deficient individuals. J. Infect. Dis. 168: 227-231.
[0213] Bixler, G. S. et al, (1989) Adv. Exp. Med. Biol V:175-180.
[0214] Constantino P, Viti S, Podda A, Velmonte M. A., Nencioni L,
Rappuoli R (1992). Development and phase 1 clinical testing of a
conjugate vaccine against meningococcus A and C. Vaccine 10:
691-698. [0215] De Velasco E A, Merkus D, Anderton S, Verheul A F
M, Lizzio E F, Van der Zee R, Van Eden W, Hoffman T, Vehoef J,
Snippe H (1995) Synthetic peptides representing T-cell epitopes act
as carriers in pneumococcal polysaccharide conjugate vaccines.
Infect Immun 63: 961-968. [0216] Dick W E, Beurret M jr.
Glycoconjugates of bacterial carbohydrate antigens. A survey and
consideration of design and preparation factors, Conjugate Vaccines
(J. M. Cruse and R. E. Lewis, eds.) Karger, Basel, 1989, p. 48.
[0217] Etlinger H M, Gillessen D, Lahm H W, Matile H, Schonfeld H
J, Trzeciak A (1990) Use of prior vaccination for the development
of new vaccines. Science 249: 423-425. [0218] Goldblatt D, Levinsky
R J, Turner M W (1992) Role of cell well polysaccharide in the
assessment of IgG antibodies to the capsular polysaccharides of
Streptococcus pneumoniae in childhood. J. Infect. Dis. 166:
632-634. [0219] Jennings H. J. and C. Lugowsky, Immunogenic
conjugates, U.S. Pat. No. 4,902,506 (1990). [0220] Holmes S J,
Granoff D M (1992) The biology of Haemophilus influenzae type b
vaccination failure. J. Infect. Dis. 165: S121-S128 [0221] Insel R
A, Anderson P W (1986). Oligosaccharide-protein conjugate vaccines
induce and prime for oligoclonal IgG antibody responses to H.
influenzae b capsular polysaccharide in human infants. J Exp Med
163: 262-269 [0222] Jennings H J, Lugowsky C (1981).
Immunochemistry of group A, B, and C meningococcal
polysaccharide-tetanus toxoid conjugates. J. Immunol 127:
1011-1018. [0223] Kaliyaperumal A, Chauhan V S, Talwar G P
Raghupathy R (1995) Carrier-induced epitope-specific regulation at
its bypass in a protein-protein conjugate. Eur J Immunol
25:3375-3380. [0224] Konadu E, Schiloach G, Bryla D. A., Robins J
B, Szu S C (1996) Synthesis, characterization, and immunological
properties in mice of conjugates composed of detoxified
lipopolysaccharides of Salmonella paratyphi A bound to tetanus
toxoid with emphasis on the role of 0 acetyles. Infect Immun 64:
2709-2715. [0225] Kumar A, Arora R, Kaur P, Chauhan V S, Sharma P
(1992) "Universal" T helper cell determinants enhance
immunogenicity of a Plasmodium falciparum merozoite surface antigen
peptide. J Immunol 148: 1499-1505. [0226] Lett, E. et al, (1994)
Infect Immun 785-792. [0227] Liptak G S, McConnochie K M, Roghmann
K J, Panzer J A (1997) Decline of pediatric admissions with
Haemophilus influenzae type b in New York state, 1982 through 1993:
Relation to immunisations. J Pediatr 130: 923-930. [0228] Marburg
S, Jorn D, Tolman R L, Arison B, McCauley J, Kniskern N, Hagopian
A, Vella P P (1986). Bimolecular chemistry of
macromolecules--synthesis of bacterial polysaccharide conjugates
with Neisseria meningitidis membrane protein. J. Am. Chem Soc 108,
5282. [0229] McNamara M K, Ward R E, Kohler H (1984) Monoclonal
idiotope vaccine against Streptococcus pneumoniae infection.
Science 226: 1325-1326. [0230] Moxon E R and Kroll J S (1990) The
role of bacterial polysaccharide capsules as virulence factors.
Curr. Top. Microbiol. Immunol. 150: 65-85. [0231] Panina-Bordignon
P, et al, (1989) Eur J Immunol. 19: 2237-2242. [0232] Robbins J B,
Schneerson R, Anderson P, Smith D H (1996) Prevention of systemic
infections, especially meningitis, caused by Haemophilus influenzae
type b: impact on public health and implications for other
polysaccharide-based vaccines. JAMA 276: 1181-1185. [0233] S.
Marburg, R. L. Tolman, and P. J. Kniskern, Covalently-modified
polyanionic bacterial polysaccharides and immunogenic protein with
bigeneric spacers, and methods of preparing such polysaccharides
and conjugates and of confirming covalency, U.S. Pat. Nos.
4,695,624 (1987) and 4,882,317 (1989). [0234] Sad S, Rao K, Arora
R, Talwar G P, Raghupathy R (1992) Bypass of carrier-induced
epitope-specific suppression using a T-helper epitope. Immunology
76: 599-603. [0235] Schneerson R, Robbins J B, Parke J C, Bell C,
Schlesselman J J, Stton A, Wang Z, Schiffman G, Karpas A, Shiloach
J (1986). Quantitative and qualitative analysis of serum antibodies
elicited in adults by Haemophilus influenzae type b and
pneumococcus type 6A capsular polysaccharide-tetanus toxoid
conjugates. Infect Immun 52: 519. [0236] Tunkel A R and Scheld W M
(1993) Pathogenesis and pathophysiology of bacterial meningitis.
Clin. Microbiol. Rev. 6: 118-136. [0237] Valmori D, Pessi A,
Bianchi E, Corradin G (1992) Use of human universally antigenic
tetanus toxin T cell epitopes as carriers for human vaccination. J
Immunol 149: 717-721.
Sequence CWU 1
1
20115PRTT-cell epitope P23TT 1Val Ser Ile Asp Lys Phe Arg Ile Phe
Cys Lys Ala Asn Pro Lys1 5 10 15216PRTT-cell epitope P32TT 2Leu Lys
Phe Ile Ile Lys Arg Tyr Thr Pro Asn Asn Glu Ile Asp Ser1 5 10
15316PRTT-cell epitope P21TT 3Ile Arg Glu Asp Asn Asn Ile Thr Leu
Lys Leu Asp Arg Cys Asn Asn1 5 10 15418PRTT-cell epitope PF T3 4Glu
Lys Lys Ile Ala Lys Met Glu Lys Ala Ser Ser Val Phe Asn Val1 5 10
15Val Asn521PRTT-cell epitope P30TT 5Phe Asn Asn Phe Thr Val Ser
Phe Trp Leu Arg Val Pro Lys Val Ser1 5 10 15Ala Ser His Leu Glu
20614PRTT-cell epitope P2TT 6Gln Tyr Ile Lys Ala Asn Ser Lys Phe
Ile Gly Ile Thr Glu1 5 10713PRTT-cell epitope HA 7Pro Lys Tyr Val
Lys Gln Asn Thr Leu Lys Leu Ala Thr1 5 10820PRTT-cell epitope HBVnc
8Pro His His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu Leu1 5
10 15Met Thr Leu Ala 20915PRTT-cell epitope HBsAg 9Phe Phe Leu Leu
Thr Arg Ile Leu Thr Ile Pro Gln Ser Leu Asp1 5 10 151016PRTT-cell
epitope MT 10Tyr Ser Gly Pro Leu Lys Ala Glu Ile Ala Gln Arg Leu
Glu Asp Val1 5 10 151120PRTT-cell epitope HSP70 11Gln Pro Ser Val
Gln Ile Gln Val Tyr Gln Gly Glu Arg Glu Ile Ala1 5 10 15Ser His Asn
Lys 20128PRTT-cell epitope Flag peptide 12Met Asp Tyr Lys Asp Asp
Asp Asp1 513657DNARecombinant N10 constructCDS(1)..(657) 13atg ggg
ggt tct cat cat cat cat cat cat ggt atg gct agc atg gat 48Met Gly
Gly Ser His His His His His His Gly Met Ala Ser Met Asp1 5 10 15tac
aag gac gac gat gat atc gaa ggt cgc aaa ggt gtt tcc atc gac 96Tyr
Lys Asp Asp Asp Asp Ile Glu Gly Arg Lys Gly Val Ser Ile Asp 20 25
30aaa ttc cgt atc ttc tgc aaa gct aac ccg aaa aaa ggt ctg aaa ttc
144Lys Phe Arg Ile Phe Cys Lys Ala Asn Pro Lys Lys Gly Leu Lys Phe
35 40 45atc atc aaa cgt tac acc ccg aac aac gaa atc gac tcc aaa ggt
atc 192Ile Ile Lys Arg Tyr Thr Pro Asn Asn Glu Ile Asp Ser Lys Gly
Ile 50 55 60cgt gaa gac aac aac atc acc ctg aaa ctg gac cgt tgc aac
aac aaa 240Arg Glu Asp Asn Asn Ile Thr Leu Lys Leu Asp Arg Cys Asn
Asn Lys65 70 75 80ggt gaa aag aag atc gct aaa atg gaa aaa gct tct
tct gtt ttc aac 288Gly Glu Lys Lys Ile Ala Lys Met Glu Lys Ala Ser
Ser Val Phe Asn 85 90 95gtt gtt aac tct aaa ggt ttc aac aac ttc acc
gtt tcc ttc tgg ctg 336Val Val Asn Ser Lys Gly Phe Asn Asn Phe Thr
Val Ser Phe Trp Leu 100 105 110cgt gtt ccg aaa gtt tcc gct tcc cac
ctg gaa aaa ggt cag tac atc 384Arg Val Pro Lys Val Ser Ala Ser His
Leu Glu Lys Gly Gln Tyr Ile 115 120 125aaa gct aac tcc aaa ttc atc
ggt atc acc gaa aaa ggt gga tct ccg 432Lys Ala Asn Ser Lys Phe Ile
Gly Ile Thr Glu Lys Gly Gly Ser Pro 130 135 140cat cat acc gcg ctg
cgc cag gcg att ctg tgc tgg ggc gaa ctg atg 480His His Thr Ala Leu
Arg Gln Ala Ile Leu Cys Trp Gly Glu Leu Met145 150 155 160acc ctg
gcg aaa gga tct ccg aaa tat gtg aaa cag aac acc ctg aaa 528Thr Leu
Ala Lys Gly Ser Pro Lys Tyr Val Lys Gln Asn Thr Leu Lys 165 170
175ctg gcg acc aaa gga tcg ttt ttt ctg ctg acc cgc att ctg acc att
576Leu Ala Thr Lys Gly Ser Phe Phe Leu Leu Thr Arg Ile Leu Thr Ile
180 185 190ccg cag tct ctg gat aaa ggc tat tct ggc ccg ctg aaa gcg
gaa att 624Pro Gln Ser Leu Asp Lys Gly Tyr Ser Gly Pro Leu Lys Ala
Glu Ile 195 200 205gcg cag cgc ctg gaa gat gtg aaa gga tcc taa
657Ala Gln Arg Leu Glu Asp Val Lys Gly Ser 210
21514218PRTRecombinant N10 construct 14Met Gly Gly Ser His His His
His His His Gly Met Ala Ser Met Asp1 5 10 15Tyr Lys Asp Asp Asp Asp
Ile Glu Gly Arg Lys Gly Val Ser Ile Asp 20 25 30Lys Phe Arg Ile Phe
Cys Lys Ala Asn Pro Lys Lys Gly Leu Lys Phe 35 40 45Ile Ile Lys Arg
Tyr Thr Pro Asn Asn Glu Ile Asp Ser Lys Gly Ile 50 55 60Arg Glu Asp
Asn Asn Ile Thr Leu Lys Leu Asp Arg Cys Asn Asn Lys65 70 75 80Gly
Glu Lys Lys Ile Ala Lys Met Glu Lys Ala Ser Ser Val Phe Asn 85 90
95Val Val Asn Ser Lys Gly Phe Asn Asn Phe Thr Val Ser Phe Trp Leu
100 105 110Arg Val Pro Lys Val Ser Ala Ser His Leu Glu Lys Gly Gln
Tyr Ile 115 120 125Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu Lys
Gly Gly Ser Pro 130 135 140His His Thr Ala Leu Arg Gln Ala Ile Leu
Cys Trp Gly Glu Leu Met145 150 155 160Thr Leu Ala Lys Gly Ser Pro
Lys Tyr Val Lys Gln Asn Thr Leu Lys 165 170 175Leu Ala Thr Lys Gly
Ser Phe Phe Leu Leu Thr Arg Ile Leu Thr Ile 180 185 190Pro Gln Ser
Leu Asp Lys Gly Tyr Ser Gly Pro Leu Lys Ala Glu Ile 195 200 205Ala
Gln Arg Leu Glu Asp Val Lys Gly Ser 210 21515432DNARecombinant N6
constructCDS(1)..(432) 15atg ggg ggt tct cat cat cat cat cat cat
ggt atg gct agc atg gat 48Met Gly Gly Ser His His His His His His
Gly Met Ala Ser Met Asp1 5 10 15tac aag gac gac gat gat atc gaa ggt
cgc aaa ggt gtt tcc atc gac 96Tyr Lys Asp Asp Asp Asp Ile Glu Gly
Arg Lys Gly Val Ser Ile Asp 20 25 30aaa ttc cgt atc ttc tgc aaa gct
aac ccg aaa aaa ggt ctg aaa ttc 144Lys Phe Arg Ile Phe Cys Lys Ala
Asn Pro Lys Lys Gly Leu Lys Phe 35 40 45atc atc aaa cgt tac acc ccg
aac aac gaa atc gac tcc aaa ggt atc 192Ile Ile Lys Arg Tyr Thr Pro
Asn Asn Glu Ile Asp Ser Lys Gly Ile 50 55 60cgt gaa gac aac aac atc
acc ctg aaa ctg gac cgt tgc aac aac aaa 240Arg Glu Asp Asn Asn Ile
Thr Leu Lys Leu Asp Arg Cys Asn Asn Lys65 70 75 80ggt gaa aag aag
atc gct aaa atg gaa aaa gct tct tct gtt ttc aac 288Gly Glu Lys Lys
Ile Ala Lys Met Glu Lys Ala Ser Ser Val Phe Asn 85 90 95gtt gtt aac
tct aaa ggt ttc aac aac ttc acc gtt tcc ttc tgg ctg 336Val Val Asn
Ser Lys Gly Phe Asn Asn Phe Thr Val Ser Phe Trp Leu 100 105 110cgt
gtt ccg aaa gtt tcc gct tcc cac ctg gaa aaa ggt cag tac atc 384Arg
Val Pro Lys Val Ser Ala Ser His Leu Glu Lys Gly Gln Tyr Ile 115 120
125aaa gct aac tcc aaa ttc atc ggt atc acc gaa aaa ggt gga tcc taa
432Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu Lys Gly Gly Ser 130
135 14016143PRTRecombinant N6 construct 16Met Gly Gly Ser His His
His His His His Gly Met Ala Ser Met Asp1 5 10 15Tyr Lys Asp Asp Asp
Asp Ile Glu Gly Arg Lys Gly Val Ser Ile Asp 20 25 30Lys Phe Arg Ile
Phe Cys Lys Ala Asn Pro Lys Lys Gly Leu Lys Phe 35 40 45Ile Ile Lys
Arg Tyr Thr Pro Asn Asn Glu Ile Asp Ser Lys Gly Ile 50 55 60Arg Glu
Asp Asn Asn Ile Thr Leu Lys Leu Asp Arg Cys Asn Asn Lys65 70 75
80Gly Glu Lys Lys Ile Ala Lys Met Glu Lys Ala Ser Ser Val Phe Asn
85 90 95Val Val Asn Ser Lys Gly Phe Asn Asn Phe Thr Val Ser Phe Trp
Leu 100 105 110Arg Val Pro Lys Val Ser Ala Ser His Leu Glu Lys Gly
Gln Tyr Ile 115 120 125Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu
Lys Gly Gly Ser 130 135 140171173DNARecombinant N19
constructCDS(1)..(1173) 17atg ggg ggt tct cat cat cat cat cat cat
ggt atg gct agc atg gat 48Met Gly Gly Ser His His His His His His
Gly Met Ala Ser Met Asp1 5 10 15tac aag gac gac gat gat atc gaa ggt
cgc aaa ggt gtt tcc atc gac 96Tyr Lys Asp Asp Asp Asp Ile Glu Gly
Arg Lys Gly Val Ser Ile Asp 20 25 30aaa ttc cgt atc ttc tgc aaa gct
aac ccg aaa aaa ggt ctg aaa ttc 144Lys Phe Arg Ile Phe Cys Lys Ala
Asn Pro Lys Lys Gly Leu Lys Phe 35 40 45atc atc aaa cgt tac acc ccg
aac aac gaa atc gac tcc aaa ggt atc 192Ile Ile Lys Arg Tyr Thr Pro
Asn Asn Glu Ile Asp Ser Lys Gly Ile 50 55 60cgt gaa gac aac aac atc
acc ctg aaa ctg gac cgt tgc aac aac aaa 240Arg Glu Asp Asn Asn Ile
Thr Leu Lys Leu Asp Arg Cys Asn Asn Lys65 70 75 80ggt gaa aag aag
atc gct aaa atg gaa aaa gct tct tct gtt ttc aac 288Gly Glu Lys Lys
Ile Ala Lys Met Glu Lys Ala Ser Ser Val Phe Asn 85 90 95gtt gtt aac
tct aaa ggt ttc aac aac ttc acc gtt tcc ttc tgg ctg 336Val Val Asn
Ser Lys Gly Phe Asn Asn Phe Thr Val Ser Phe Trp Leu 100 105 110cgt
gtt ccg aaa gtt tcc gct tcc cac ctg gaa aaa ggt cag tac atc 384Arg
Val Pro Lys Val Ser Ala Ser His Leu Glu Lys Gly Gln Tyr Ile 115 120
125aaa gct aac tcc aaa ttc atc ggt atc acc gaa aaa ggt gga tct ccg
432Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu Lys Gly Gly Ser Pro
130 135 140cat cat acc gcg ctg cgc cag gcg att ctg tgc tgg ggc gaa
ctg atg 480His His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu
Leu Met145 150 155 160acc ctg gcg aaa gga tct ccg aaa tat gtg aaa
cag aac acc ctg aaa 528Thr Leu Ala Lys Gly Ser Pro Lys Tyr Val Lys
Gln Asn Thr Leu Lys 165 170 175ctg gcg acc aaa gga tcg ttt ttt ctg
ctg acc cgc att ctg acc att 576Leu Ala Thr Lys Gly Ser Phe Phe Leu
Leu Thr Arg Ile Leu Thr Ile 180 185 190ccg cag tct ctg gat aaa ggc
tat tct ggc ccg ctg aaa gcg gaa att 624Pro Gln Ser Leu Asp Lys Gly
Tyr Ser Gly Pro Leu Lys Ala Glu Ile 195 200 205gcg cag cgc ctg gaa
gat gtg aaa gga tct gtt tcc atc gac aaa ttc 672Ala Gln Arg Leu Glu
Asp Val Lys Gly Ser Val Ser Ile Asp Lys Phe 210 215 220cgt atc ttc
tgc aaa gct aac ccg aaa aaa ggt ctg aaa ttc atc atc 720Arg Ile Phe
Cys Lys Ala Asn Pro Lys Lys Gly Leu Lys Phe Ile Ile225 230 235
240aaa cgt tac acc ccg aac aac gaa atc gac tcc aaa ggt atc cgt gaa
768Lys Arg Tyr Thr Pro Asn Asn Glu Ile Asp Ser Lys Gly Ile Arg Glu
245 250 255gac aac aac atc acc ctg aaa ctg gac cgt tgc aac aac aaa
ggt gaa 816Asp Asn Asn Ile Thr Leu Lys Leu Asp Arg Cys Asn Asn Lys
Gly Glu 260 265 270aag aag atc gct aaa atg gaa aaa gct tct tct gtt
ttc aac gtt gtt 864Lys Lys Ile Ala Lys Met Glu Lys Ala Ser Ser Val
Phe Asn Val Val 275 280 285aac tct aaa ggt ttc aac aac ttc acc gtt
tcc ttc tgg ctg cgt gtt 912Asn Ser Lys Gly Phe Asn Asn Phe Thr Val
Ser Phe Trp Leu Arg Val 290 295 300ccg aaa gtt tcc gct tcc cac ctg
gaa aaa ggt cag tac atc aaa gct 960Pro Lys Val Ser Ala Ser His Leu
Glu Lys Gly Gln Tyr Ile Lys Ala305 310 315 320aac tcc aaa ttc atc
ggt atc acc gaa aaa ggt gga tct ccg cat cat 1008Asn Ser Lys Phe Ile
Gly Ile Thr Glu Lys Gly Gly Ser Pro His His 325 330 335acc gcg ctg
cgc cag gcg att ctg tgc tgg ggc gaa ctg atg acc ctg 1056Thr Ala Leu
Arg Gln Ala Ile Leu Cys Trp Gly Glu Leu Met Thr Leu 340 345 350gcg
aaa gga tct ccg aaa tat gtg aaa cag aac acc ctg aaa ctg gcg 1104Ala
Lys Gly Ser Pro Lys Tyr Val Lys Gln Asn Thr Leu Lys Leu Ala 355 360
365acc aaa gga tcg ttt ttt ctg ctg acc cgc att ctg acc att ccg cag
1152Thr Lys Gly Ser Phe Phe Leu Leu Thr Arg Ile Leu Thr Ile Pro Gln
370 375 380tct ctg gat aaa gga tcc taa 1173Ser Leu Asp Lys Gly
Ser385 39018390PRTRecombinant N19 construct 18Met Gly Gly Ser His
His His His His His Gly Met Ala Ser Met Asp1 5 10 15Tyr Lys Asp Asp
Asp Asp Ile Glu Gly Arg Lys Gly Val Ser Ile Asp 20 25 30Lys Phe Arg
Ile Phe Cys Lys Ala Asn Pro Lys Lys Gly Leu Lys Phe 35 40 45Ile Ile
Lys Arg Tyr Thr Pro Asn Asn Glu Ile Asp Ser Lys Gly Ile 50 55 60Arg
Glu Asp Asn Asn Ile Thr Leu Lys Leu Asp Arg Cys Asn Asn Lys65 70 75
80Gly Glu Lys Lys Ile Ala Lys Met Glu Lys Ala Ser Ser Val Phe Asn
85 90 95Val Val Asn Ser Lys Gly Phe Asn Asn Phe Thr Val Ser Phe Trp
Leu 100 105 110Arg Val Pro Lys Val Ser Ala Ser His Leu Glu Lys Gly
Gln Tyr Ile 115 120 125Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu
Lys Gly Gly Ser Pro 130 135 140His His Thr Ala Leu Arg Gln Ala Ile
Leu Cys Trp Gly Glu Leu Met145 150 155 160Thr Leu Ala Lys Gly Ser
Pro Lys Tyr Val Lys Gln Asn Thr Leu Lys 165 170 175Leu Ala Thr Lys
Gly Ser Phe Phe Leu Leu Thr Arg Ile Leu Thr Ile 180 185 190Pro Gln
Ser Leu Asp Lys Gly Tyr Ser Gly Pro Leu Lys Ala Glu Ile 195 200
205Ala Gln Arg Leu Glu Asp Val Lys Gly Ser Val Ser Ile Asp Lys Phe
210 215 220Arg Ile Phe Cys Lys Ala Asn Pro Lys Lys Gly Leu Lys Phe
Ile Ile225 230 235 240Lys Arg Tyr Thr Pro Asn Asn Glu Ile Asp Ser
Lys Gly Ile Arg Glu 245 250 255Asp Asn Asn Ile Thr Leu Lys Leu Asp
Arg Cys Asn Asn Lys Gly Glu 260 265 270Lys Lys Ile Ala Lys Met Glu
Lys Ala Ser Ser Val Phe Asn Val Val 275 280 285Asn Ser Lys Gly Phe
Asn Asn Phe Thr Val Ser Phe Trp Leu Arg Val 290 295 300Pro Lys Val
Ser Ala Ser His Leu Glu Lys Gly Gln Tyr Ile Lys Ala305 310 315
320Asn Ser Lys Phe Ile Gly Ile Thr Glu Lys Gly Gly Ser Pro His His
325 330 335Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu Leu Met
Thr Leu 340 345 350Ala Lys Gly Ser Pro Lys Tyr Val Lys Gln Asn Thr
Leu Lys Leu Ala 355 360 365Thr Lys Gly Ser Phe Phe Leu Leu Thr Arg
Ile Leu Thr Ile Pro Gln 370 375 380Ser Leu Asp Lys Gly Ser385
39019723DNARecombinant N11 constructCDS(1)..(723) 19atg ggg ggt tct
cat cat cat cat cat cat ggt atg gct agc atg gat 48Met Gly Gly Ser
His His His His His His Gly Met Ala Ser Met Asp1 5 10 15tac aag gac
gac gat gat atc gaa ggt cgc aaa ggt gtt tcc atc gac 96Tyr Lys Asp
Asp Asp Asp Ile Glu Gly Arg Lys Gly Val Ser Ile Asp 20 25 30aaa ttc
cgt atc ttc tgc aaa gct aac ccg aaa aaa ggt ctg aaa ttc 144Lys Phe
Arg Ile Phe Cys Lys Ala Asn Pro Lys Lys Gly Leu Lys Phe 35 40 45atc
atc aaa cgt tac acc ccg aac aac gaa atc gac tcc aaa ggt atc 192Ile
Ile Lys Arg Tyr Thr Pro Asn Asn Glu Ile Asp Ser Lys Gly Ile 50 55
60cgt gaa gac aac aac atc acc ctg aaa ctg gac cgt tgc aac aac aaa
240Arg Glu Asp Asn Asn Ile Thr Leu Lys Leu Asp Arg Cys Asn Asn
Lys65 70 75 80ggt gaa aag aag atc gct aaa atg gaa aaa gct tct tct
gtt ttc aac 288Gly Glu Lys Lys Ile Ala Lys Met Glu Lys Ala Ser Ser
Val Phe Asn 85 90 95gtt gtt aac tct aaa ggt ttc aac aac ttc acc gtt
tcc ttc tgg ctg 336Val Val Asn Ser Lys Gly Phe Asn Asn Phe Thr Val
Ser Phe Trp Leu 100 105 110cgt gtt ccg aaa gtt tcc gct tcc cac ctg
gaa aaa ggt cag tac atc 384Arg Val Pro Lys Val Ser Ala Ser His Leu
Glu Lys Gly Gln Tyr Ile 115 120 125aaa gct aac tcc aaa ttc atc ggt
atc acc gaa aaa ggt gga tct ccg 432Lys Ala Asn Ser Lys Phe Ile Gly
Ile Thr Glu Lys Gly Gly Ser Pro 130 135 140cat cat acc gcg ctg
cgc cag gcg att ctg tgc tgg ggc gaa ctg atg 480His His Thr Ala Leu
Arg Gln Ala Ile Leu Cys Trp Gly Glu Leu Met145 150 155 160acc ctg
gcg aaa gga tct ccg aaa tat gtg aaa cag aac acc ctg aaa 528Thr Leu
Ala Lys Gly Ser Pro Lys Tyr Val Lys Gln Asn Thr Leu Lys 165 170
175ctg gcg acc aaa gga tcg ttt ttt ctg ctg acc cgc att ctg acc att
576Leu Ala Thr Lys Gly Ser Phe Phe Leu Leu Thr Arg Ile Leu Thr Ile
180 185 190ccg cag tct ctg gat aaa ggc tat tct ggc ccg ctg aaa gcg
gaa att 624Pro Gln Ser Leu Asp Lys Gly Tyr Ser Gly Pro Leu Lys Ala
Glu Ile 195 200 205gcg cag cgc ctg gaa gat gtg aaa gga tct cag ccg
tct gtt cag att 672Ala Gln Arg Leu Glu Asp Val Lys Gly Ser Gln Pro
Ser Val Gln Ile 210 215 220cag gtg tat cag ggt gaa cgt gaa atc gca
tct cat aac aaa gga tcc 720Gln Val Tyr Gln Gly Glu Arg Glu Ile Ala
Ser His Asn Lys Gly Ser225 230 235 240taa 72320240PRTRecombinant
N11 construct 20Met Gly Gly Ser His His His His His His Gly Met Ala
Ser Met Asp1 5 10 15Tyr Lys Asp Asp Asp Asp Ile Glu Gly Arg Lys Gly
Val Ser Ile Asp 20 25 30Lys Phe Arg Ile Phe Cys Lys Ala Asn Pro Lys
Lys Gly Leu Lys Phe 35 40 45Ile Ile Lys Arg Tyr Thr Pro Asn Asn Glu
Ile Asp Ser Lys Gly Ile 50 55 60Arg Glu Asp Asn Asn Ile Thr Leu Lys
Leu Asp Arg Cys Asn Asn Lys65 70 75 80Gly Glu Lys Lys Ile Ala Lys
Met Glu Lys Ala Ser Ser Val Phe Asn 85 90 95Val Val Asn Ser Lys Gly
Phe Asn Asn Phe Thr Val Ser Phe Trp Leu 100 105 110Arg Val Pro Lys
Val Ser Ala Ser His Leu Glu Lys Gly Gln Tyr Ile 115 120 125Lys Ala
Asn Ser Lys Phe Ile Gly Ile Thr Glu Lys Gly Gly Ser Pro 130 135
140His His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu Leu
Met145 150 155 160Thr Leu Ala Lys Gly Ser Pro Lys Tyr Val Lys Gln
Asn Thr Leu Lys 165 170 175Leu Ala Thr Lys Gly Ser Phe Phe Leu Leu
Thr Arg Ile Leu Thr Ile 180 185 190Pro Gln Ser Leu Asp Lys Gly Tyr
Ser Gly Pro Leu Lys Ala Glu Ile 195 200 205Ala Gln Arg Leu Glu Asp
Val Lys Gly Ser Gln Pro Ser Val Gln Ile 210 215 220Gln Val Tyr Gln
Gly Glu Arg Glu Ile Ala Ser His Asn Lys Gly Ser225 230 235 240
* * * * *